

# Medication for the Treatment of Alcohol Use Disorder

## CONTENTS

<b>Introduction.....</b>	<b>1</b>
<b>Considering Medications .....</b>	<b>2</b>
<b>Screening and Assessing Patients .....</b>	<b>7</b>
Screening for Risky Alcohol Use.....	7
Assessing the Need for Medication-Assisted Treatment.....	7
<b>Developing a Treatment Plan and Selecting a Medication.....</b>	<b>9</b>
Setting Goals for Medication-Assisted Treatment.....	9
Components of the Treatment Plan .....	9
Educating the Patient and Obtaining Informed Consent .....	9
Evaluating the Need for Medically Managed Detoxification .....	10
Integrating Pharmacologic and Nonpharmacologic Therapies.....	11
Addressing Co-Occurring Disorders .....	11
Treating Adolescents and Young Adults .....	12
Treating Pregnant and Postpartum Women.....	12
Treating Older Adults .....	12
Selecting a Medication .....	13
<b>Medication-Assisted Treatment .....</b>	<b>18</b>
Initiating Treatment with Disulfiram .....	18
Initiating Treatment with Naltrexone.....	18
Initiating Treatment with Acamprosate.....	20
Treating People with Co-Occurring Disorders.....	20
<b>Monitoring Patient Progress.....</b>	<b>20</b>
Monitoring .....	20
Adjusting the Treatment Plan.....	21
<b>Summary .....</b>	<b>23</b>
<b>Appendix A: Members of the Consensus Panel, Staff, and Consultants .....</b>	<b>24</b>
<b>Appendix B: Sources of Helpful Information .....</b>	<b>26</b>
<b>Appendix C: Acknowledgments .....</b>	<b>29</b>
<b>References .....</b>	<b>30</b>

# INTRODUCTION

Current evidence shows that medications are underused in the treatment of alcohol use disorder, including alcohol abuse and dependence.\* This is of concern because of the high prevalence of alcohol problems in the general population.<sup>1,2</sup> For example, data show that an estimated 10 percent to 20 percent of patients seen in primary care or hospital settings have a diagnosable alcohol use disorder.<sup>3,4</sup> People who engage in risky drinking often have physical and social problems related to their alcohol use. Problems with alcohol influence the incidence, course, and treatment of many other medical and psychiatric conditions.<sup>2</sup>

Yet, of the 18.0 million people who met the criteria for alcohol dependence or abuse in 2013, only a small subset (1.4 million) received any type of formal treatment (excluding mutual-help groups)—ranging from a single meeting with a counselor to participation in a specialized treatment program.<sup>3</sup>

Although many experts in addiction believe that patients with moderate or severe alcohol-related problems should be offered medication-assisted treatment (MAT) on a routine basis,<sup>1</sup> considerable resistance to the use of MAT persists. A diagnosis of alcohol use disorder continues to carry significant social exclusion, which affects both the individual who receives the diagnosis and the health care professionals to whom that individual may turn for care. In part, the social exclusion continues because of a lack of understanding of alcohol use disorder as a treatable medical disorder<sup>2</sup> even though, more than 50 years ago, the American Medical Association (AMA) affirmed that dependence on alcohol and other drugs is a medical disorder.<sup>5</sup> The AMA encouraged physicians and other clinicians, health care organizations, and policymakers to frame all their activities and decisions in ways that reflect that fact.

## Alcohol Use Disorder: A Comparison Between DSM-IV and DSM-5

“In May 2013, the American Psychiatric Association issued the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Although there is considerable overlap between DSM-5 and DSM-IV, the prior edition, there are several important differences: DSM-IV described two distinct disorders, alcohol abuse and alcohol dependence, with specific criteria for each. DSM-5 integrates the two DSM-IV disorders, alcohol abuse and alcohol dependence, into a single disorder called alcohol use disorder (AUD) with mild, moderate, and severe subclassifications. Under DSM-5, anyone meeting any two of the 11 criteria during the same 12-month period would receive a diagnosis of AUD. The severity of an AUD—mild, moderate, or severe—is based on the number of criteria met:

- **Mild:** The presence of 2 to 3 symptoms
- **Moderate:** The presence of 4 to 5 symptoms
- **Severe:** The presence of 6 or more symptoms

The DSM-5 eliminates legal problems as a criterion, adds craving as a criterion for an AUD diagnosis and modifies some of the criteria descriptions with updated language.”

—National Institute on Alcohol Abuse and Alcoholism<sup>6</sup>

To clarify the situation, the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) jointly convened a Consensus Panel on New and Emerging Pharmacotherapies for Alcohol Use Disorders and Related Comorbidities (see Appendix A). The panel, which brought together experts in alcohol research, clinical care, medical education, and public policy, reviewed current evidence on the effectiveness of available medications for the treatment of alcohol use disorders and developed guidance for the use of medications in clinical practice.<sup>1</sup> The panel’s guidance is summarized in this document.

\* Within this document “alcohol abuse” and “alcohol dependence” are used when discussing medication indications or research that is based upon this terminology. For a summary of important differences between DSM-IV and DSM-5, please see the box on this page.

## CONSIDERING MEDICATIONS

Direct involvement of physicians and other health care professionals in identifying and treating alcohol use disorder is possible, practical, and necessary. The medications described here have been shown to be effective in, and are approved by the Food and Drug Administration (FDA) for, the management of alcohol dependence or the prevention of relapse to alcohol use.<sup>7,8,9,10,11</sup>

Specifically:

- **Acamprosate calcium** is indicated for the maintenance of abstinence from alcohol in patients dependent on alcohol who are abstinent at treatment initiation.
- **Disulfiram** is an aid in the management of selected patients who want to remain in a state of enforced sobriety so that supportive and psychotherapeutic treatment may be applied to best advantage.
- **Oral naltrexone** (naltrexone hydrochloride tablet) is indicated for the treatment of alcohol dependence.
- **Extended-release injectable naltrexone** is indicated for the treatment of alcohol dependence in patients who have been able to abstain from alcohol in an outpatient setting.

Clinicians should consider prescribing one of these medications when treating a patient who is dependent on alcohol or who has stopped drinking but is experiencing problems including cravings or relapses. Patients with moderate or severe alcohol use disorder, including those who have physiologic dependence or who are experiencing cravings and have not improved in response to psychosocial approaches alone, are particularly strong candidates for medication-assisted treatment.<sup>1,2</sup>

Medications should be prescribed as part of a comprehensive treatment approach that includes counseling and other psychosocial therapies (through referral to a psychiatrist, psychologist, or professional counselor) and social supports (through participation in Alcoholics Anonymous and other mutual-help programs).<sup>1,2</sup>

Table 1 summarizes information about each medication approved by the FDA for the treatment of alcohol use disorder and/or the prevention of relapse to alcohol use.

**TABLE 1: Medications Approved for Use in the Treatment of Alcohol Use Disorder<sup>†</sup>**

	<b>Disulfiram</b>	<b>Naltrexone oral and extended release injectable formulations</b>	<b>Acamprosate delayed-release tablets</b>
<b>Frequency of Administration</b>	Daily	Daily (oral) or monthly (extended-release injectable)	Three times per day
<b>Principal Action</b>	<p><b>When</b> taken in combination with alcohol, causes a significant physical reaction, involving nausea/vomiting, flushing, and heart palpitations. The knowledge that such reactions are likely if alcohol is consumed acts as a deterrent to drinking.</p> <p><b>Given</b> sufficient amounts of alcohol in the patient's system, more severe reactions may occur, such as respiratory depression, cardiovascular collapse, arrhythmias, myocardial infarction, acute congestive heart failure, unconsciousness, convulsions, and death.</p>	<p><b>Blocks</b> opiate receptors that are involved in the rewarding effects of drinking and craving for alcohol.</p> <p><b>Extended-release</b> injectable naltrexone is administered every 4 weeks, thereby minimizing opportunities for nonadherence, as compared with daily oral ingestion. The monthly injection also produces a more consistent and predictable blood level of the drug, because the depot injection bypasses first-pass metabolism.</p>	<p><b>Is</b> thought to reduce symptoms of protracted abstinence by counteracting the imbalance between the glutamatergic and GABAergic systems associated with chronic alcohol exposure and alcohol withdrawal.</p>
<b>Clinical Uses/Ideal Candidates</b>	<p><b>Candidates</b> include patients dependent on alcohol who have completed alcohol withdrawal. Ideally, candidates are committed to abstinence and willing to take disulfiram under the supervision of a family member or treatment program.</p>	<p><b>Oral</b> naltrexone and extended-release injectable naltrexone are indicated for the treatment of alcohol dependence in patients who can abstain from alcohol in an outpatient setting before the initiation of treatment. Naltrexone has not been shown to be effective in patients who are drinking at treatment initiation.</p> <p><b>Both</b> formulations may have the greatest benefit in patients who can discontinue drinking on their own for several days before treatment initiation.</p> <p><b>Extended-release</b> injectable naltrexone is also indicated for the prevention of relapse to opioid dependence following detoxification.</p>	<p><b>Acamprosate</b> is indicated for the maintenance of abstinence in patients who are dependent on alcohol and are abstinent at treatment initiation.</p> <p><b>The</b> efficacy of acamprosate in promoting abstinence has not been demonstrated in subjects who have not completed detoxification or who have not achieved alcohol abstinence before beginning treatment.</p>

<sup>†</sup> This table highlights some properties of each medication. It does not provide complete information and is not intended as a substitute for the package inserts or other drug reference sources used by clinicians (see <http://www.dailymed.nlm.nih.gov> for current package inserts). For patient information about these and other drugs, visit the National Library of Medicine's MedlinePlus (<http://www.medlineplus.gov>). Whether a medication should be prescribed and in what amount are matters to be discussed between an individual and his or her health care provider. The prescribing information provided here is not a substitute for the clinician's judgment, and the National Institutes of Health and SAMHSA accept no liability or responsibility for use of the information in the care of individual patients.

	Disulfiram	Naltrexone oral and extended release injectable formulations	Acamprosate delayed-release tablets
<b>Contraindications</b>	<p><b>Contraindicated</b> in the presence of severe myocardial disease or coronary occlusion, psychoses, pregnancy, and in those with high levels of impulsivity, suicidality, and hypersensitivity to disulfiram or to other thiuram derivatives used in pesticides and rubber vulcanization.</p> <p><b>Patients</b> who are taking or have recently taken metronidazole, paraldehyde, alcohol, or alcohol-containing preparations (e.g., cough syrups, tonics) should not be given disulfiram.</p> <p><b>Disulfiram</b> labeling also includes several important precautions regarding drug–drug interactions. See the package insert for specific contraindications.</p>	<p><b>Contraindicated</b> in patients receiving opioid analgesics and those receiving long-term opioid therapy or anticipating a need for opioids (e.g., surgery), because it could precipitate a severe opioid withdrawal or block opioid analgesia; patients currently dependent on opioids, including those being maintained on opioid agonists such as methadone or partial agonists such as buprenorphine; patients in acute opioid withdrawal; patients who have failed the naloxone challenge test or whose urine tests positive for opioids.</p> <p><b>Contraindicated</b> in patients with a history of sensitivity to polylactide-co-glycolide, carboxymethyl cellulose, or any components of the diluent used for the injectable medication.</p> <p><b>It</b> should not be given to patients whose body mass precludes intramuscular (IM) injection with the 2-inch needle provided. Inadvertent subcutaneous injection may cause a severe injection-site reaction.</p> <p><b>Although</b> not in current labeling, the consensus of the panel is that use should be avoided in patients with serum aminotransferase levels greater than five times the upper limit of normal, except where the benefits outweigh the risks.</p>	<p><b>Contraindicated</b> in patients with severe renal impairment and in those who have a known hypersensitivity to the drug or its components.</p>

	Disulfiram	Naltrexone oral and extended release injectable formulations	Acamprosate delayed-release tablets
<b>Warnings</b>	<p><b>Use</b> with caution in patients with heart disease, diabetes, hypothyroidism, epilepsy, cerebral damage, chronic or acute nephritis, acute hepatitis or other hepatic diseases, and in patients older than 60.</p> <p><b>Hepatic</b> toxicity (including hepatic failure resulting in liver transplantation or death) has been infrequently reported. Severe and sometimes fatal hepatitis associated with disulfiram may develop after many months of therapy. Hepatic toxicity has occurred in patients with or without a history of abnormal liver function.</p> <p><b>Patients</b> should be advised to immediately notify their physician of any early symptoms of hepatitis, including fatigue, weakness, malaise, anorexia, nausea, vomiting, jaundice, or dark urine.</p> <p><b>Liver</b> function tests (taken at baseline and 10–14 days later) are suggested to detect any hepatic dysfunction that may result from disulfiram therapy. In addition, complete blood counts and serum chemistries, including liver function tests, should be monitored.</p> <p><b>Psychotic</b> reactions have been noted, attributable to the unmasking of underlying psychoses in patients.</p>	<p><b>Cases</b> of hepatitis and clinically significant liver dysfunction were observed in association with extended-release injectable naltrexone treatment. Discontinue use of naltrexone in the event of symptoms or signs of acute hepatitis.</p> <p><b>Use</b> with caution in patients with moderate to severe renal impairment.</p> <p><b>Patients</b> should take no opioids, including opioid-containing medications, for a minimum of 7 days before starting naltrexone to avoid precipitating opioid withdrawal.</p> <p><b>Patients</b> needing opioid analgesia or patients with a history of opioid use disorder may respond to lower doses of opioids after treatment with extended-release injectable naltrexone. Failure to carefully titrate opioid dose could result in potentially life-threatening opioid intoxication and overdose.</p> <p><b>Patients</b> should be told of the serious consequences of trying to overcome the opioid blockade.</p>	<p><b>Before</b> initiating treatment with acamprosate, evaluate the patient's renal function through a standard panel for urea, electrolytes, and serum creatinine to rule out severe renal impairment.</p> <p><b>For</b> patients with moderate renal impairment (creatinine clearance of 30–50 mL/min), a reduced dose of acamprosate (one 333 mg tablet 3 times a day) is recommended.</p> <p><b>Because</b> of elevated risk of diminished renal function in people ages 65 or older, baseline and frequent renal function tests are important in this population.</p>

	Disulfiram	Naltrexone oral and extended release injectable formulations	Acamprosate delayed-release tablets
<b>Use in Pregnant and Postpartum Women</b>	<p><b>Pregnancy:</b> The FDA has not assigned a pregnancy category. The safe use of this drug in pregnancy has not been established. Therefore, disulfiram should be used during pregnancy only when, in the judgment of the physician, the probable benefits outweigh the possible risks.</p> <p><b>Nursing:</b> Do not give disulfiram to nursing mothers.</p>	<p><b>Pregnancy:</b> FDA Pregnancy Category C<sup>‡</sup></p> <p><b>Nursing:</b> Transfer of naltrexone and 6β-naltrexol into human milk has been reported with oral naltrexone. Because animal studies have shown that naltrexone has a potential for tumorigenicity and other serious adverse reactions in nursing infants, an individualized treatment decision should be made whether a nursing mother will need to discontinue breastfeeding or discontinue naltrexone.</p>	<p><b>Pregnancy:</b> FDA Pregnancy Category C<sup>‡</sup></p> <p><b>Nursing:</b> It is not known whether acamprosate is excreted in human milk.</p>

SOURCE: SAMHSA and NIAAA. (2012, September). *Report of the SAMHSA-NIAAA Consensus Panel on New and Emerging Pharmacotherapies for Alcohol Use Disorders and Related Comorbidities*. Rockville, MD: SAMHSA.

<sup>‡</sup> Animal studies have shown an adverse effect on the fetus and there are no adequate, well-controlled studies in humans, but potential benefits may warrant use of the drug in some pregnant women despite potential risks.



## SCREENING AND ASSESSING PATIENTS

Clinicians should routinely screen their patients for at-risk drinking, provide brief interventions as needed, and assess for alcohol use disorder when indicated.<sup>2</sup>

### Screening for Risky Alcohol Use

Universal screening for alcohol problems can be conducted concurrently with screening for other medical disorders as part of a routine examination. By systematically screening every patient with a validated screening tool, the clinician can effectively identify patients with risky or dependent levels of alcohol use. This approach has been shown to be superior to a case-finding approach.

Screening also should be conducted before prescribing one of the many medications that may interact negatively with alcohol or if a patient reports using an over-the-counter product or herbal preparation that may precipitate an adverse reaction.

Screening is especially important in patients who:

- Are pregnant or trying to conceive.
- Are at risk for binge drinking or heavy drinking.
- Have health problems that may be induced or exacerbated by alcohol (e.g., cardiac arrhythmia, depression or anxiety, dyspepsia, insomnia, liver disease, a history of traumatic injury).
- Have one or more chronic health problems (e.g., diabetes, heart disease, hypertension, gastrointestinal [GI] disorders, chronic pain) that are not responding to treatment.<sup>7</sup>
- Have social or legal problems that may be caused or worsened by alcohol use (e.g., marital/family issues, driving-while-under-the-influence convictions).

Screening can be conducted through use of a simple, validated self-report instrument such as the *Alcohol Use Disorders Identification Test* (AUDIT) ([http://www.who.int/hq/2001/WHO\\_MSD\\_MSB\\_01.6a.pdf](http://www.who.int/hq/2001/WHO_MSD_MSB_01.6a.pdf)), which takes fewer than 5 minutes to complete, or a single interview question: “How many times in the past year have you had \_\_\_\_ or more drinks in a day?” (five drinks for men and four drinks for women). The single question can be used at any time, either in conjunction with AUDIT or alone.<sup>7</sup> Study results have shown that, when used in a primary care setting, the single question was 82 percent sensitive in detecting individuals who had alcohol problems.<sup>12</sup>

A useful overview of screening and intervention strategies can be found in a document called *Alcohol Misuse: Screening and Behavioral Counseling Interventions in Primary Care* (<http://www.uspreventiveservicestaskforce.org/uspstf/uspdrin.htm>) (see Appendix B). Many U.S. primary care physicians rely on these United States Preventive Services Task Force recommendations to guide how they conduct preventive practice. Clinicians should also consider using Screening, Brief Intervention, and Referral to Treatment (SBIRT), an approach in which screening is followed up as appropriate with brief intervention, and with referral to treatment for those needing more extensive care (<http://www.samhsa.gov/sbirt>) (see Appendix B).

### Assessing the Need for Medication-Assisted Treatment

A patient who reports one or more heavy drinking days in the past year (or who has an AUDIT score greater than 8) should receive further assessment.<sup>2,7,8,9,10,11</sup> Consideration should be given to the factors motivating a patient toward treatment, the patient’s stage of change, the potential for relapse, the severity of any concomitant medical and psychiatric problems, the patient’s ability to tolerate medications, and whether the patient is pregnant (in which case, medications associated with adverse physical effects, such as disulfiram, should be avoided).

**Patient History.** Although the evidence supporting inclusion of each element is not conclusive, consensus opinion is that an assessment should include a medical and psychiatric history, a substance use history, and an evaluation of family and psychosocial supports.<sup>13</sup>

Information from family members and significant others can provide useful perspectives on the patient’s status, as can communication with or records from clinicians who treated the patient in the past.<sup>13</sup>

It also is advisable to access the patient’s prescription drug use history through the state’s prescription drug monitoring program (PDMP), where available,<sup>13</sup> to detect unreported use of other medications, such as opioid analgesics or sedative-hypnotics, that may interact negatively

with alcohol or with alcohol treatment medications.

**Physical Examination.** The physical examination should evaluate neurocognitive function, identify sequelae of alcohol use, and look for evidence of hepatic dysfunction.<sup>14</sup>

Although many patients with alcohol use disorder have no specific abnormal findings on physical examination, when present, these abnormal findings provide evidence of the severity of a patient's alcohol problem. For example, longstanding alcohol consumption may be marked by many classic features, such as physical manifestations of cirrhosis, encephalopathy, and vitamin deficiencies. Alcohol consumption may also provoke tachycardia (including supraventricular tachycardias), tremor of the hand or tongue, elevated blood pressure, hepatosplenomegaly, a tender liver edge, peripheral neuropathy, spider angiomas, conjunctival injection, and unexplained trauma.<sup>2,14,15,16</sup>

*Laboratory tests help confirm the presence of heavy drinking and identify alcohol-related damage.*

**Laboratory Testing.** Laboratory tests help confirm the presence of heavy drinking and identify alcohol-related damage. Initial and follow-up laboratory testing can help motivate patients and reinforce their progress in treatment.<sup>2</sup> Although no single laboratory test can definitively point to an alcohol use disorder diagnosis in the absence of other information,<sup>14</sup> the following tests can be helpful in identifying heavy drinking and possible alcohol-related abnormalities:<sup>16,17</sup>

- Blood alcohol levels are useful measures of recent alcohol consumption and can indicate physical or legal incapacity to perform specific tasks, including driving.
- Carbohydrate-deficient transferrin (CDT), gamma-glutamyl transpeptidase (GGT), and aspartate aminotransferase (AST) levels can be useful biomarkers because they often are elevated in people who have chronically consumed significant amounts of alcohol.<sup>16</sup> Some studies suggest that biomarkers such as AST, GGT, and CDT are most useful when used in combination.<sup>16,17,18,19</sup>

- Tests for ethyl glucuronide (EtG), an alcohol metabolite, are highly sensitive for alcohol; however, this sensitivity is a potential drawback as well as a strength, because exposure to even small amounts of alcohol (e.g., those found in some foods and cosmetics) can trigger a positive test result.<sup>16,17,20</sup> However, use of appropriate laboratory cutoffs make it more likely that a positive test is an indication of recent alcohol use.<sup>20</sup>
- Phosphatidylethanol, another alcohol metabolite, is a promising new biomarker that is highly sensitive in detecting chronic drinking (three or more drinks a day for 1 or 2 weeks). It can be detected in the blood for 2 to 4 weeks after drinking has stopped.<sup>16,20,21,22</sup>

Several laboratory tests can help the clinician establish a patient's overall health status and identify alcohol-related damage and contraindications to the use of specific medications.<sup>23,24</sup> These include:

- **Complete blood count:** Alcohol overuse can cause anemia and have direct toxic effects on bone marrow. An assessment of hematologic laboratory indices is useful when considering pharmacologic treatment of alcohol use disorder. Many people who are alcohol dependent have elevated corpuscular volume (macrocytosis).
- **Testing for vitamin deficiencies:** Individuals with alcohol use disorder may not consume a healthful diet, resulting in vitamin deficiencies that lead to abnormal cellular function. For example, deficiencies in thiamine, folic acid, and pyridoxine are seen in people with physiological alcohol dependence, and those deficiencies contribute to abnormal cell function. Vitamin deficiencies may also lead to Wernicke-Korsakoff/amnestic syndrome in patients whose alcohol consumption is very excessive.
- **Hepatic and renal testing:** The use of medications to treat alcohol use disorder requires evaluation of organ systems that are involved in the metabolism and excretion of those medications. For example, naltrexone and disulfiram should be used with caution in patients who have liver disease, whereas naltrexone and acamprosate should be used with caution in patients with renal impairment. Therefore, hepatic and renal system testing

should be done as part of the patient assessment.

- **Other tests:** Initial laboratory work should include a urine toxicology screen to assess for

other substances, and women of childbearing age should have a pregnancy test.

## DEVELOPING A TREATMENT PLAN AND SELECTING A MEDICATION

If a patient's initial assessment supports a diagnosis of moderate or severe alcohol use disorder, the next step is to develop a comprehensive treatment plan.<sup>24</sup>

### Setting Goals for Medication-Assisted Treatment

The provider and patient should mutually agree on an initial goal and be willing to refine and revise that goal as treatment progresses.<sup>2</sup> For example, in working with a patient who is unwilling to set a goal of complete abstinence, the clinician should support the patient in reducing his or her drinking as an interim goal, while maintaining that complete abstinence is the safer strategy, with a greater chance of long-term success.<sup>7</sup>

Certain conditions warrant complete abstinence from alcohol rather than a reduction in use. These involve individuals who are or may become pregnant, are taking a medication that may cause a harmful drug interaction, or have a medical or psychiatric disorder that is associated with or exacerbated by alcohol use.<sup>7,24</sup>

If a patient engages in risky drinking but does not meet the criteria for an alcohol use disorder, the clinician should use his or her professional judgment in helping the patient decide whether reducing or abstaining from alcohol is the more appropriate goal, based on factors such as a family history of alcohol problems and the patient's age or history of traumatic injuries related to drinking.<sup>24</sup>

It may be helpful to provide the patient with a copy of National Institute on Alcohol Use and Alcoholism's booklet *Rethinking Drinking* or to refer the patient to the associated Web site (see Appendix B).

### Components of the Treatment Plan

Steps to achieve the patient's goal should be outlined in a treatment plan, which should be developed in consultation with the patient and address the following points:<sup>13</sup>

- The medication and other therapies to be employed, with a rationale for their use
- Schedules for follow-up office visits and laboratory testing to monitor the patient's progress and health status
- Reasons for participation in mutual-help groups
- Involvement of family or significant others in treatment
- A plan for treating co-occurring medical or psychiatric conditions and other substance use disorders, including smoking
- Criteria for discontinuing the use of medication or other therapies and referring the patient for a higher level of care, if indicated

Whenever a medication is to be used, the treatment plan should include steps that will promote medication adherence. Depending on the needs of the patient, these might include specific strategies for remembering to take medications, use of blister card packs or pill boxes, a schedule for monitoring medication adherence that reflects the patient's history of adherence to other medication regimens, and steps to involve the patient's family members in monitoring adherence.<sup>2,7</sup>

### Educating the Patient and Obtaining Informed Consent

Before treatment begins, the patient should understand what to expect, including how the proposed medication works and the associated risks and benefits. This is best achieved through face-to-face discussions and the use of written

educational materials (see Appendix B for sources of helpful information).

Elements of effective patient education include the following points:<sup>2,13</sup>

- Information about alcohol use disorder as a chronic medical disorder
- A description of what to expect from treatment
- Information about the medication and the reasons it was selected, including a discussion of potential risks and benefits and the time to full effect
- For women of childbearing age, explanation of the importance of using an effective birth control method
- Clear information about what to do if the patient resumes alcohol use after a period of abstinence
- The importance of informing all physicians and dentists that the patient is taking a medication for alcohol use disorder, to avoid inadvertent drug interactions, especially when surgery (including dental surgery) is being considered
- Symptoms that should be reported to the prescribing physician
- A discussion of the importance of concurrent psychosocial treatment and participation in a mutual-help group
- Plans for follow-up care

The patient should be advised to carry a medical alert card identifying the medication-assisted treatment, describing potential adverse effects (e.g., symptoms of a disulfiram–alcohol reaction), and providing contact information for the treating physician or institution in an emergency.<sup>13</sup>

The fact that a patient has received and understands this information should be documented in the patient record. Clinicians also are advised to obtain a written informed consent from the patient before initiating treatment.<sup>13</sup>

## Evaluating the Need for Medically Managed Detoxification

Alcohol withdrawal syndrome can be severe and potentially fatal, so it is particularly important to assess the need for medically managed withdrawal.<sup>25</sup> Patients who need medically supervised detoxification may need to be referred to an addiction specialist or addiction treatment program that can provide medically monitored withdrawal treatment.

Withdrawal generally begins within 24 to 48 hours after the blood alcohol level drops and can persist for 5 to 7 days. Symptoms include restlessness, irritability, anxiety, and agitation; anorexia, nausea, and vomiting; tremor; elevated heart rate; increased blood pressure; insomnia, intense dreaming, and nightmares; poor concentration and impaired memory and judgment; increased sensitivity to sound, light, and tactile sensations; auditory, visual, or tactile hallucinations; delusions (usually of a paranoid or persecutory nature); grand mal seizures; hyperthermia; delirium with disorientation concerning time, place, person, and situation; and fluctuations in level of consciousness.<sup>25</sup>

In assessing the likelihood and potential severity of withdrawal, the most useful clinical factors are the patient's previous withdrawal experience and the number of previous withdrawals (treated or untreated), with three or four withdrawal episodes indicating an increased likelihood that severe withdrawal symptoms will occur unless adequate medical care is provided.<sup>26</sup>

Use of a standardized clinical rating instrument for withdrawal, such as the *Clinical Institute Withdrawal Assessment for Alcohol Scale, Revised* (CIWA-Ar) ([https://umem.org/files/uploads/1104212257\\_CIWA-Ar.pdf](https://umem.org/files/uploads/1104212257_CIWA-Ar.pdf)), is helpful because it guides the clinician through multiple domains of alcohol withdrawal and allows for semi-quantitative assessment of nausea, tremor, autonomic hyperactivity, anxiety, agitation, perceptual disturbances, headache, and disorientation.<sup>26,27</sup> In multiple studies, the CIWA-Ar has been found to have high reliability and validity, and it takes only 2 to 5 minutes to complete.<sup>26</sup>

Some benzodiazepines are effective in treating the symptoms of alcohol withdrawal. For example, diazepam carries a labeled indication for relief of acute agitation, tremor, impending or acute delirium tremens, and hallucinosis in acute alcohol withdrawal. Chlordiazepoxide also is frequently used for the management of alcohol withdrawal symptoms.



## Integrating Pharmacologic and Nonpharmacologic Therapies

Some patients may respond to psychosocial interventions and others to medication therapy alone, but most patients benefit from a combination of these approaches. The various approaches—medications for moderate or severe alcohol use disorder, professional counseling, and mutual-help groups—are complementary; they address different aspects of alcohol use disorder: neurobiological, psychological, and social. Offering the full range of effective treatments increases patient choice and the potential for a positive outcome, as no single approach is universally successful.<sup>7</sup>

**Psychosocial Treatments.** Psychosocial treatments can enhance adherence to the treatment plan, including use of prescribed medications, and thus improve treatment outcomes. Conversely, to the extent that they reduce craving and help patients maintain abstinence, medications may help patients be more receptive to psychosocial interventions.<sup>2,28</sup>

Almost all studies of medications for the treatment of alcohol use disorder have included some type of counseling, and it is recommended that all patients for whom these medications are prescribed receive at least brief counseling. Evidence is accumulating that weekly or biweekly brief (i.e., 15–20 minutes) counseling sessions combined with use of a medication is an effective treatment for many patients in early recovery.<sup>2,7,9</sup> This counseling typically focuses on encouraging abstinence, adherence to the medication regimen, and participation in mutual-help groups.<sup>7</sup>

Although psychiatrists may be able to deliver psychosocial therapies onsite, most clinicians need to refer patients for individual or group therapy.<sup>2</sup>

**Encouraging Participation in Mutual-Help Programs.** The support of a mutual-help group can be helpful to long-term recovery. The oldest, best known, and most accessible mutual-help program is offered by Alcoholics Anonymous (AA). Patients may resist attending AA meetings and may fear that disclosure of medication use will make them unwelcome.<sup>2</sup> Although some AA members have negative attitudes toward medication, the organization itself supports

appropriate medication use.<sup>29</sup> Providers should encourage patients to try different group meetings until they find one that is a good fit. Lists of local meetings to give to patients can be obtained from <http://www.aa.org>.

Other mutual-help groups, although not as universally available as AA, have a strong presence in many communities. Contact information for several groups that may be helpful to patients and their families is provided in Appendix B.

## Addressing Co-Occurring Disorders

Research studies show that the most effective way to treat co-occurring disorders is through integrated treatment,<sup>30,31,32</sup> which is defined as any mechanism by which treatment interventions for multiple co-occurring disorders are delivered within the context of a primary treatment relationship or service setting. The term *co-occurring* acknowledges the need for a unified treatment approach to meet the substance use, mental health, and related needs of a patient and, thus, is the preferred model of treatment.<sup>2</sup> Integrated treatment assumes that each disorder is primary and in need of simultaneous care.

It is not always possible to provide truly integrated care in primary care settings, although standardized psychosocial treatments have been developed that are more readily provided in general practice settings.<sup>1,31</sup> When providers cannot provide a full range of onsite care, they need to identify resources in their practice community and develop relationships with those providers to streamline and coordinate care as much as possible. This includes developing and maintaining resources for psychosocial services.<sup>1,7</sup> In addition, the patient may need assistance with obtaining a referral, securing an initial appointment within a reasonable time frame, and addressing issues with health insurance coverage.

When medication management and addiction treatment services are delivered by separate providers, close coordination and integration of services is essential. All individuals involved in the patient's treatment, including addiction medicine specialists, need to establish close linkages and open communications.<sup>31,32</sup>

## Treating Adolescents and Young Adults

Empirical validation of the value of medication-assisted treatment in adolescents is lacking. Moreover, none of the available medications is approved by the FDA for use in people younger than age 18. Therefore, younger adolescents in need of treatment should be referred to a clinician or program specializing in adolescent addiction.<sup>1,33</sup>

However, in older adolescents and young adults, the limitations of available psychosocial interventions for youth and the demonstrated effectiveness of pharmacologic interventions in adults suggest that it may be reasonable to consider pharmacologic treatments for patients in this age group.<sup>34,35</sup>

There are no specific safety contraindications for older adolescents/young adults for the medications discussed here, and available information supports the safe and judicious use of medications in this population.<sup>36</sup> This is particularly true of older adolescents and young adults who have severe alcohol use disorder, as well as those who have not achieved success with psychosocial interventions alone and those who exhibit more adult patterns of moderate and severe alcohol use disorder.<sup>37</sup>

## Treating Pregnant and Postpartum Women

Pregnancy and postpartum care present opportunities to screen and intervene for alcohol use disorder, which is clearly associated with fetal abnormalities and long-term cognitive problems in offspring. In fact, research has not identified any safe level of drinking during pregnancy.<sup>38</sup> Use of alcohol during pregnancy may result in miscarriage, stillbirth, or premature delivery. Complications seen in the infant may include fetal alcohol syndrome or fetal alcohol spectrum disorder.

Unfortunately, none of the medications used to treat alcohol use disorder have been shown in clinical trials to be absolutely safe for pregnant or nursing women. Therefore, these medications should be used during pregnancy only when, in the judgment of the physician, the probable benefits outweigh the possible risks.<sup>39</sup> Pregnant or nursing patients should be referred to an

addiction specialist or a specialist in managing high-risk pregnancies for care.<sup>40</sup>

## Treating Older Adults

Alcohol and other substance use are significant problems among older adults, in whom alcohol use disorder is associated with many health and social problems that increase the risk of hospitalization, nursing home placement, and death.<sup>41,42,43</sup> A study projected that the number of adults ages 50 and older with a substance use disorder will double from 2.8 million (the annual average in the period from 2002 through 2006) to 5.7 million in 2020.<sup>44</sup>

*Pharmacotherapies for alcohol use disorder appear to be as effective and safe for older adults as for younger adults.*

Accurately diagnosing an alcohol use disorder in an older adult can be done more effectively when clinicians are cognizant of the following challenges faced by this population group:<sup>45</sup>

- **Shame:** Older adults are more likely to hide their substance-related problems because they are more likely to feel shame and less likely to seek help or talk about it.
- **Problem ignored or minimized by family:** Family members may feel ashamed, be in denial, ignore the problem, believe the problem is not serious, or feel that their older relatives have a right to drink or use drugs.
- **Misdiagnosis:** Health care practitioners often mistake alcohol or drug problems for symptoms of other conditions that are common among older adults, such as depression or dementia.

Pharmacotherapies for alcohol use disorder appear to be as effective and safe for older adults as for younger adults. However, because older adults are more likely than their younger counterparts to have comorbid medical problems and thus to be using multiple medications and have decreased ability to eliminate medications, care must be taken to avoid adverse drug events.<sup>45</sup>

As a result, the following factors need to be considered when prescribing pharmacotherapy to older adults:<sup>45,46</sup>

- Dose reductions and frequent renal function tests may be necessary when prescribing acamprosate to individuals in whom decreased renal function (creatinine clearance rate <70 mL/min/1.73 m<sup>2</sup>) is evident.
- In patients ages 61 and older, disulfiram doses may need to be reduced. Disulfiram interacts with multiple drugs, so caution should be exercised in prescribing it to older adults at risk for polypharmacy.

## Selecting a Medication

The FDA has approved three oral medications (disulfiram, acamprosate, and naltrexone) and one injectable medication (extended-release injectable naltrexone) for the treatment of alcohol dependence or the prevention of relapse to alcohol use.<sup>7,24</sup> In addition to factors specific to each medication, the clinician should consider the patient's past experience with particular medication-assisted treatment medications; beliefs and opinions about which pharmacotherapy may be most helpful; level of motivation for abstinence; medical status and contraindications for each medication; and history of medication adherence.<sup>2</sup>

Although further research with large patient samples is required before definitive advice can be offered on which medication to select for a particular patient, information for matching patients to particular pharmacotherapies is summarized below.<sup>24,40,47,48,49</sup> Medications are listed in the approximate order in which the FDA approved them for the treatment of alcohol dependence.

*The FDA has approved three oral medications and one injectable medication for treatment of alcohol dependence or prevention of relapse to alcohol use.*

**Disulfiram.** Approved by the FDA as an alcohol abuse deterrent in 1951, disulfiram disrupts the metabolism of alcohol, resulting in an unpleasant reaction, which can be severe whenever an individual taking disulfiram consumes alcohol.<sup>50,51,52,53,54</sup>

**Mechanism of Action.** The disulfiram reaction is caused by a blockade of aldehyde dehydrogenase, which causes an accumulation of acetaldehyde when alcohol is ingested. When this occurs, the physical reaction can include nausea, flushing, and heart palpitations.<sup>40</sup> Unlike other medications approved to treat alcohol use disorder, disulfiram does not directly affect opiate, gaba-aminobutyric acid, or glutamate receptors in the brain. Disulfiram blocks dopamine-beta-hydroxylase in the brain, thereby increasing dopamine levels and reducing noradrenaline levels.<sup>51</sup>

**Formulation.** Disulfiram is manufactured as a white to off-white odorless and almost tasteless powder. It is supplied in 250 mg and 500 mg tablets for oral administration.<sup>50</sup>

**Dosing and Administration.** The initial and average maintenance dose is 250 mg per day (doses range from 125 mg to a maximum dose of 500 mg per day). The disulfiram tablet is taken by mouth once a day; it may be crushed and mixed with water, coffee, tea, milk, soft drink, or fruit juice.<sup>50</sup> Faulty bioactivation in some patients can yield too low a concentration of the active metabolite needed to inhibit aldehyde dehydrogenase, and the 500 mg dose may be more effective in these patients.<sup>52</sup> Patients who experience mild side effects (as described later in this section) may obtain relief by reducing the dose to 125 mg daily.<sup>51</sup>

**Efficacy.** The effectiveness of disulfiram in the prevention and limitation of relapse to alcohol use is supported by multiple studies.<sup>47,48</sup> It should be noted that disulfiram was approved prior to the requirement that drugs be shown to be effective before being marketed was enacted. An evidence report from the Agency for Healthcare Research and Quality concluded that four placebo-controlled randomized clinical trials of oral disulfiram produced mixed results.<sup>49</sup> Although disulfiram was shown to reduce the frequency of drinking days in two trials, in neither study did it improve relapse rates compared with placebo. Two studies that examined patient adherence with oral disulfiram found it to be low,<sup>53,54</sup> and a third study had a 46 percent dropout rate.<sup>55</sup>

Investigators who argue that disulfiram is effective in preventing relapse to alcohol use frequently emphasize the importance of the

circumstances in which it is administered. In particular, the level and quality of supervision a patient receives while taking disulfiram are believed to be important components of its success.<sup>55,56</sup> Some studies have found that court-ordered disulfiram therapy promotes efficacy by increasing adherence to the disulfiram regimen.<sup>57</sup> Use of incentives, patient contracts, the cooperation of a significant other in fostering adherence, the use of regular reminders to the patient, and patient behavioral counseling and social support may enhance disulfiram efficacy by improving adherence. Overall, methodologic limitations and mixed results make it difficult to state with certainty what percentage of patients benefit from disulfiram.<sup>1</sup> However, disulfiram is a medication that should be considered for patients with no contraindications and who might have major consequences should they use alcohol.

**Safety.** The severity of a disulfiram–alcohol interaction is proportional to the dose of disulfiram and the amount of alcohol consumed. A reaction lasts 30 to 60 minutes in mild cases. In more severe cases, the reaction can continue for several hours or until the alcohol is metabolized. When effects are severe, palliative and supportive measures may be needed to restore blood pressure and treat shock.<sup>50</sup>

Other safety issues include both minor side effects and more serious adverse reactions. Minor side effects, which typically occur during the first 2 weeks of therapy, include skin/acneiform eruptions, headache, allergic dermatitis, impotence, mild drowsiness, fatigue, and metallic or garlic-like aftertaste.<sup>2,50</sup>

Serious adverse reactions, although rare,<sup>51</sup> include the following conditions:<sup>2,50</sup>

- **Optic neuritis:** Usually diagnosed after a patient complains of visual disturbances, optic neuritis is addressed by discontinuing disulfiram and conducting (or referring the patient for) an ophthalmologic examination.
- **Peripheral neuritis, polyneuritis, peripheral neuropathy:** Usually diagnosed after a patient complains of paresthesias (numbness or tingling), these conditions require that disulfiram be discontinued. A neurological evaluation should be conducted.
- **Hepatitis, including cholestatic and fulminant hepatitis, as well as hepatic failure:** When symptoms of hepatic dysfunction are reported

or observed, liver function tests should be obtained. When clinical or laboratory evidence of hepatic dysfunction is found, disulfiram should be discontinued immediately and liver function and other symptoms monitored closely.

**Drug Interactions.** There is evidence that disulfiram interacts with a number of drugs, including benzodiazepines, isoniazid, rifadin (Rifampin®), metronidazole, oral anticoagulants such as warfarin, oral hypoglycemics, phenytoin, and theophylline. The potential severity of some drug interactions makes it essential that patients be cautioned to report all medications they are taking and not to start any new medication without checking with the disulfiram prescriber.<sup>14,53</sup>

**Clinical Recommendations.** Patients who are good candidates for treatment with disulfiram include those who are motivated for treatment and want to achieve abstinence, who are medically appropriate, who can receive supervised dosing, and who understand the consequences of drinking alcohol while taking disulfiram. It may be an appropriate short-term therapy for a patient in recovery who anticipates being in a situation that may trigger craving for alcohol (e.g., a family holiday visit) and who requests an additional incentive to remain abstinent.<sup>2,53,54,55,56,57</sup>

**Naltrexone.** Naltrexone hydrochloride is a long-acting opioid antagonist. The FDA approved oral naltrexone for the treatment of alcohol dependence or alcoholism in 1994. The low rate of retention and adherence encountered with oral naltrexone led to the development of the extended-release injectable formulation, which the FDA approved for the treatment of alcohol use disorder in 2006.<sup>2,24</sup>

*The actual neurobiological mechanisms by which naltrexone induces the reduction in alcohol consumption observed in alcohol-dependent patients is not entirely understood. Preclinical data suggest the involvement of the endogenous opioid system.*

**Mechanism of Action.** Naltrexone has affinity for the mu, kappa, and delta opiate receptors. The actual neurobiological mechanisms by which



naltrexone induces the reduction in alcohol consumption observed in alcohol-dependent patients is not entirely understood. Preclinical data suggest the involvement of the endogenous opioid system.<sup>58</sup>

As an antagonist at the mu receptor, naltrexone may reduce the urge to consume alcohol through two mechanisms:

1. Suppression of alcohol-mediated beta-endorphin stimulation of dopamine neurons in the nucleus accumbens
2. Reduction of beta-endorphin disinhibition of the tonic inhibition of dopamine cells by gamma-aminobutyric acid neurons in the ventral tegmental area<sup>47,59,60</sup>

Extended-release injectable naltrexone is metabolized in the liver to the opioid antagonist 6 $\beta$ -naltrexol.<sup>61</sup> Two peak blood levels occur after injection: a transient initial peak occurs approximately 2 hours after injection and a second peak occurs approximately 2 days later. About 14 days after injection, the blood level slowly begins to decline in a linear fashion. The absorption of extended-release naltrexone is mediated by its gradual and prolonged release for 2 to 4 weeks after injection through hydrolysis of copolymer microspheres.<sup>7,24</sup>

**Formulation.** Oral naltrexone is marketed in 50 mg tablets.<sup>7,24</sup>

Extended-release injectable naltrexone was developed by embedding the drug molecule within microspheres composed of a biodegradable copolymer, resulting in release of the active ingredient over a period of approximately 4 weeks.<sup>62,63</sup> It is packaged in a kit containing a vial of naltrexone as a dry powder, which must be suspended in a liquid diluent immediately before use. Each kit contains a syringe and five needles: one for mixing the microspheres with the diluent and four needles (two 1.5-inch needles and two 2-inch needles) for injecting the suspension into the upper outer quadrant of the gluteal muscle.<sup>63</sup>

Kits must be refrigerated during storage but should be brought to room temperature approximately 45 minutes before an injection is given. The suspended microspheres in solution must be mixed vigorously to prevent clumping, which can clog the needle during injection.<sup>63</sup>

**Dosing and Administration.** The oral naltrexone tablet is taken by mouth once a day. The dose recommended for most patients is 50 mg per day, given in a single dose.<sup>2,7</sup> GI side effects are common and dose dependent, so patients with GI side effects should have a trial of therapy at a lower dose.

The approved dose of extended-release naltrexone is 380 mg, given approximately once a month. Clinical trial data confirm earlier studies indicating that there is no need to adjust the dose for the patient's body weight.<sup>63</sup>

Extended-release injectable naltrexone is administered by intramuscular (IM) gluteal injection. It is retained at the site of injection so that its active compound is released consistently over approximately 4 weeks,<sup>63</sup> and measurable levels may be observed for longer than 1 month.

**Efficacy.** Oral naltrexone has been shown to reduce relapse to heavy drinking, which is defined as three or more drinks per day for women and four or more for men.<sup>59,60,64</sup> In a systematic review of 11 double-blind, placebo-controlled trials, researchers found that oral naltrexone, when combined with psychosocial treatments, reduced relapse rates at 3 months in patients with alcohol dependence.<sup>59</sup> (Almost all studies were done in patients who were abstinent at baseline.) Short-term outcomes in favor of naltrexone included fewer patients relapsing to alcohol dependence (38% with naltrexone versus 60% with placebo), fewer patients returning to drinking (61% versus 69%), reduced craving for alcohol, and fewer drinking days. Thus, it is especially useful in patients who have a history of drinking relapses.<sup>65</sup>

Extended-release injectable naltrexone is approved for use only in patients who can refrain from drinking for several days before treatment begins—a subgroup of the patient population in whom efficacy has been demonstrated. For example, in a 6-month, randomized, double-blind, placebo-controlled trial involving 624 individuals, patients who received a 380 mg dose of extended-release injectable naltrexone had a 25 percent reduction in heavy drinking days compared with those receiving placebo. The effect was greater in males.<sup>66</sup> A secondary analysis found that patients who had 4 or more days of abstinence before beginning treatment with extended-release injectable naltrexone

experienced particularly good treatment outcomes.<sup>67</sup>

*A side effect unique to extended-release injectable naltrexone is injection-site reaction, which involves pain or tenderness at the injection site.*

**Safety.** Naltrexone generally is well tolerated, although it has the potential to precipitate severe opioid withdrawal in patients who are opioid dependent.<sup>2</sup> Common side effects include nausea, vomiting, headaches, dizziness, fatigue, anxiety, and somnolence, with nausea and vomiting the most frequently reported.<sup>59,60,64,65,66,67,68</sup> Less common side effects include diarrhea, constipation, chest pains, joint/muscle pain, rash, insomnia, excessive thirst, loss of appetite, perspiration, mild depression, increased tears, and delayed ejaculation.<sup>2,24</sup>

More serious adverse reactions, with suggestions for management, include the following.<sup>59,60</sup>

- **Precipitated opioid withdrawal:** To mitigate withdrawal symptoms, discontinue naltrexone, provide supportive treatments (i.e., hydration and antispasmodic and antidiarrheal medications) until the symptoms resolve, and provide a  $\beta$ 2-agonist such as clonidine. Watch for clonidine side effects, including dizziness, hypotension, fatigue, and headache.
- **Hepatic toxicity:** Discontinue naltrexone.
- **Naltrexone overdose:** Treat the patient symptomatically under close supervision. Contact a poison control center for current information.

A side effect unique to extended-release injectable naltrexone is injection-site reaction, which involves pain or tenderness at the injection site, usually resolving in 2 to 5 days. Swelling, erythema, bruising, and pruritus may occur, generally as the result of an inadvertent subcutaneous injection. Serious reactions include induration, cellulitis, hematoma, abscess, sterile abscess, and necrosis. Rarely, these reactions require surgical intervention, such as debridement of necrotic tissue, which can result in significant scarring. To prevent problems,

providers should be trained in proper techniques for IM injections.<sup>63</sup>

**Drug Interactions.** Potential drug interactions involve cough and cold preparations, antidiarrheal medications, thioridazine, yohimbine, and nonsteroidal anti-inflammatory drugs (which can elevate liver enzymes).

As noted earlier, naltrexone blocks the effects of opioid analgesics.<sup>13</sup> For more information, see the discussion of Special Considerations in Pain Management on page 18.<sup>13,14,68,69</sup>

**Clinical Recommendations: Oral Naltrexone.** Oral naltrexone is most effective when prescribed for patients who are highly motivated and/or supported with observed daily dosing and who are abstinent at the time treatment is initiated.<sup>70,71</sup> Naltrexone also appears to be effective in the following patient populations:

- Patients who have a history of opioid use disorder and who are seeking treatment for an alcohol use disorder. Naltrexone reduces the reinforcing effects of and curbs cravings for both opioids and alcohol.
- Patients with intense craving for alcohol during treatment. These individual may experience greater medication benefit than patients with low levels of craving for alcohol.<sup>72</sup>
- Patients who have a family history of alcohol use disorder. Both laboratory studies and clinical trials suggest that patients with a family history of alcohol problems may benefit more from treatment with naltrexone than patients who do not have such a history.<sup>73</sup>

**Clinical Recommendations: Extended-Release Injectable Naltrexone.** Extended-release injectable naltrexone benefits people appropriate for treatment with oral naltrexone, as well as the following.<sup>1,68,69,74</sup>

- Patients who are abstinent at initiation of treatment. Extended-release injectable naltrexone has not been shown to be effective in patients who are drinking at the time treatment is initiated.
- Patients who are seeking treatment for moderate or severe alcohol use disorder while in recovery from co-occurring opioid use disorder. The FDA approved extended-release injectable naltrexone in 2010 for the

prevention of relapse to opioid dependence, following opioid detoxification.

**Acamprosate.** Acamprosate is a delayed-release synthetic compound that is indicated for maintaining abstinence in patients who are alcohol dependent and are abstinent at the time treatment is initiated.<sup>75</sup> The FDA approved the medication for the treatment of alcohol use disorder in 2004.<sup>7</sup>

**Mechanisms of Action.** Although the precise mechanisms of action of acamprosate are not yet known, they appear to involve beneficial modulation of the glutamatergic neurotransmitter system (including antagonism of the mGlu5 metabotropic glutamate receptor) to counteract the imbalance between the glutamatergic and GABAergic systems associated with chronic alcohol exposure and alcohol withdrawal.<sup>75</sup>

**Formulation.** Acamprosate is supplied as enteric-coated 333 mg tablets.<sup>7</sup>

**Dosing and Administration.** Two 333 mg delayed-release tablets are taken by mouth three times a day, with or without food (a lower dose may be effective with some patients and must be used with those with impaired renal function). Pills must be swallowed whole, not crushed or broken.<sup>7,76</sup>

**Efficacy.** Acamprosate has been shown to be an effective treatment for dependence on alcohol, with no abuse potential and no significant interaction with medications commonly used to treat substance use and mental disorders.<sup>76</sup> Acamprosate's efficacy is primarily due to its ability to reduce the negative symptoms associated with the period immediately following alcohol withdrawal.<sup>77</sup>

**Safety.** Acamprosate has a good safety profile: no development of tolerance has been reported, there appears to be no risk of overdose, and there is no clinically significant interaction between acamprosate and other medications.

The most common side effect is diarrhea, which usually is mild and transient, typically disappearing within the first few weeks of treatment.<sup>78</sup> Less common side effects include intestinal cramps and flatulence, headache, increased or decreased libido, insomnia, anxiety, muscle weakness, and dizziness.

Rare but serious side effects include suicidal ideation and suicide attempts. In such patients, acamprosate should be discontinued and the patient monitored for worsening of depression.<sup>76</sup> A psychiatric consultation should be obtained and/or an antidepressant medication prescribed as needed.

**Drug Interactions.** There are no known drug interactions with acamprosate.<sup>14,24</sup>

**Clinical Recommendations.** Research on patient characteristics has not definitively identified particular characteristics that would predict which patients would benefit most from acamprosate.<sup>77</sup> However, evidence suggests that acamprosate may be most effective for the following types of patients:<sup>59,79</sup>

- Patients who are abstinent from alcohol at the time treatment is initiated and who are motivated to maintain abstinence. A study found that these patients had better outcomes with acamprosate than did patients who wanted only to reduce their drinking.<sup>78</sup>
- Patients with hepatic disease or those who are being treated with opioids for pain or addiction. Acamprosate is eliminated renally and does not affect endogenous or exogenous opioids.
- Patients who are coping with multiple medical issues and who are taking many other medications. There are no clinically significant drug interactions with acamprosate, so it can be a safe medication for many patients taking other medications.

## MEDICATION-ASSISTED TREATMENT

A patient who is being considered for medication-assisted treatment must be free of the contraindications listed in Table 1, including severe medical or psychiatric problems that would make the individual a poor candidate for treatment with a medication.<sup>1,2</sup>

The following steps are recommended for initiating treatment with any of the medications approved for the management of moderate or severe alcohol use disorder or the prevention of relapse to alcohol use:<sup>1,2,7</sup>

- Educate the patient about medication-assisted treatment and the specific medication being recommended.
- Obtain informed consent for medication-assisted treatment.
- Complete a medical, psychiatric, and substance use history, including history of cardiovascular disease, diabetes, thyroid disease, seizure disorder, central nervous system impairment, and kidney or liver disease.
- Determine which prescription and over-the-counter medications the patient is taking, including herbal preparations.
- Perform a physical examination, baseline liver and kidney function tests, urine toxicology screen, and (in women) a pregnancy test.
- Assess the patient for allergies to the proposed medication and to other medications.
- For women, assess reproductive status, including current pregnancy or plans to become pregnant or to breastfeed.

### Initiating Treatment with Disulfiram

Steps in initiating treatment with disulfiram are as follows:<sup>2,55,56</sup>

- Wait until the patient has abstained from alcohol for at least 12 hours and/or until the breath or blood alcohol level is zero.
- Perform an electrocardiogram if clinically indicated (e.g., in a patient with a history of heart disease).
- Confirm the absence of allergy to disulfiram.

- Perform the following tests to confirm abstinence and determine baselines after stabilization:
  - a. Breath or blood alcohol tests, if clinically indicated to confirm abstinence
  - b. Liver function tests: alanine aminotransferase, aspartate aminotransferase, gamma glutamyl-transferase, alkaline phosphatase, lactate dehydrogenase, bilirubin, total protein, albumin, prothrombin time
  - c. Complete blood count and routine chemistries, if clinically indicated
  - d. Kidney function tests: routine blood urea nitrogen, creatinine

### Initiating Treatment with Naltrexone

Naltrexone has not been shown to be effective in patients who are drinking at treatment initiation.

The clinician should consider how best to induct a prospective patient into treatment with extended-release injectable naltrexone.

Advise all patients being treated for alcohol use disorder that it is imperative to notify health care providers of any recent use of opioids or any history of opioid use disorder before starting extended-release injectable naltrexone, to avoid precipitation of opioid withdrawal. A urine drug screen should be conducted to verify abstinence before beginning induction.<sup>80</sup> If patients are to be treated for both alcohol and opioid substance use disorder, they should be off all opioids, including prescription opioid analgesics, for a minimum of 7 to 10 days before starting naltrexone.<sup>81</sup> Patients transitioning from opioid agonist therapy to extended-release injectable naltrexone may be vulnerable to precipitation of withdrawal symptoms for as long as 2 weeks. Ensure that patients understand that withdrawal precipitated by administration of an opioid antagonist is different from the experience of spontaneous withdrawal that occurs with discontinuation of opioids in a dependent individual. Withdrawal precipitated by an opioid antagonist may be severe enough to require hospitalization.



When discontinuing naltrexone for patients with a history of co-occurring opioid use disorder, advice on opioid overdose prevention should be provided. After a period of abstinence from opioids, tolerance is greatly reduced. This means a previously tolerated amount of opioid could result in opioid overdose. Patients discontinuing opioid antagonist therapy in order to receive pain management with opioid analgesics should also be advised of this risk. Consider providing patients at risk of opioid overdose with a prescription for naloxone. SAMHSA's *Opioid Overdose Toolkit* includes strategies for developing such a plan to address emergency reversal of actual or suspected opioid overdose.<sup>82</sup>

Pretreatment with oral naltrexone is not required before induction onto extended-release injectable naltrexone.<sup>63,68</sup>

**Dosing and Administration.** For appropriate candidates, the recommended dose of extended-release injectable naltrexone is 380 mg, delivered intramuscularly approximately every 30 days, alternating buttocks for each subsequent injection. The following cautions should be observed:<sup>24,63,68</sup>

- Injectable naltrexone should be administered only by a medical professional (a physician, nurse, physician assistant or nurse practitioner) who knows how to administer IM gluteal injections.
- Injectable naltrexone is packaged in a kit containing a vial of naltrexone as a dry powder that must be reconstituted with a liquid diluent immediately before use. Kits must be refrigerated during storage but should be brought to room temperature approximately 45 minutes before an injection is given. The reconstituted microspheres in solution must be mixed vigorously to prevent clumping, which can clog the needle during injection.
- A syringe and five needles are provided: one for mixing the microspheres with the diluent and four needles (two 1.5-inch needles and two 2-inch needles) for injecting the suspension into the upper outer quadrant of the gluteal muscle. Body habitus should be assessed before each injection for each patient to ensure that needle length is adequate for IM administration. Injectable naltrexone must be administered only with

one of the administration needles supplied in the carton. A spare administration needle of each size is provided in case of clogging.

- Proper IM injection technique is essential. Serious injection-site reactions, sometimes requiring extensive surgical debridement, have been observed with extended-release injectable naltrexone. It has been reported that these severe reactions may be more common if the product is inadvertently administered subcutaneously rather than intramuscularly.
- The medication should be administered every 4 weeks. If a dose is delayed or missed, the next injection should be administered as soon as possible. However, it is not recommended that the medication be readministered at less than 4-week intervals.
- It is not recommended that the medication be administered at a dose higher than 380 mg.

Clinicians are advised to download prescribing information on extended-release naltrexone at <http://dailymed.nlm.nih.gov/dailymed/index.cfm>.

### Special Considerations in Pain

**Management.** As discussed earlier, both oral and extended-release naltrexone block the effects of opioid analgesics. However, pain management for patients using extended-release injectable naltrexone can be even more complicated than for those taking oral naltrexone, because of the long-acting nature of the injectable formulation. In an emergency, regional analgesia, conscious sedation, use of non-opioid analgesics, or general anesthesia may be needed for pain management.<sup>2,63</sup>

*Pain management for patients using extended-release injectable naltrexone can be even more complicated than for those taking oral naltrexone, because of the long-acting nature of the injectable formulation.*

If regional anesthesia is not used, then a larger amount of the opioid analgesic may be needed to override the opioid blockade. This may result in respiratory depression that is deeper and more prolonged than usual. For this reason, a rapid-onset, short-acting opioid analgesic that minimizes the duration of respiratory depression is preferred. The amount administered should be

titrated to the needs of the patient, who should be monitored closely by trained medical personnel.<sup>1,2</sup>

## Initiating Treatment with Acamprosate

Acamprosate typically is initiated 5 days after the cessation of alcohol use. The drug typically reaches full effectiveness in 5 to 8 days.<sup>2,75,76</sup>

Acamprosate therapy should be continued even if a patient relapses to alcohol use.<sup>1</sup>

## Treating People with Co-Occurring Disorders

**Co-Occurring Psychiatric Disorders.** The use of pharmacotherapy in people with co-occurring psychiatric disorders typically involves the following considerations:<sup>30,31,83,84,85</sup>

- Naltrexone and acamprosate may be used in combination with psychiatric medications. There are no known drug interactions between those classes of medication and either drug.
- If a patient exhibits chronic psychiatric symptoms (e.g., depression, mood lability, psychosis, anxiety), concurrent pharmacologic treatment of the alcohol use disorder and the psychiatric comorbidity should be considered.
- If the patient exhibits symptoms of chronic depression or substance-induced depression that limits recovery potential, antidepressant

therapy in the absence of contraindications (e.g., a history of mania or hypomania) should be considered.

- Disulfiram is contraindicated in the presence of psychosis because of the risk that it will exacerbate psychotic symptoms.
- Disulfiram may increase blood levels of tricyclic antidepressants and long-acting hepatically metabolized benzodiazepines, thereby increasing the effects of those medications.

## Co-Occurring Medical Conditions and Complications.

Individuals with alcohol use disorder are at high risk for co-occurring medical conditions as a result of their heavy drinking and greater risk of concurrent drug use (which is particularly problematic if it involves injection drug use), behavioral and social factors such as unprotected sex and homelessness, or lack of regular medical care.<sup>85,86,87</sup> Alcohol can also interfere with balance and coordination, thus predisposing individuals to falls and other injuries. Patients who present to emergency departments and trauma centers with serious injuries are far more likely than members of the general population to have engaged in recent use of alcohol.<sup>88</sup>

Moreover, alcohol affects virtually every organ system. Women are more susceptible to many of the effects of alcohol at lower doses than men because of reduced first-pass metabolism of alcohol and lower average body weights.<sup>89</sup>

# MONITORING PATIENT PROGRESS

As is the case with other chronic relapsing disorders, patients diagnosed with an alcohol use disorder require long-term monitoring and support, as well as periodic adjustment of the treatment regimen.

## Monitoring

Monitoring patient progress is an ongoing process, during which the patient is assessed on three dimensions: (1) adherence to the treatment plan; (2) ability to maintain abstinence or reduced drinking, duration of periods of abstinence or reduced drinking, and levels of craving; and (3) overall health status and social functioning.<sup>1,3,7</sup> With this information, the clinician can modify the

treatment plan, decide whether to continue pharmacotherapy, and address co-occurring medical, psychiatric, and substance use issues.

**Sources of Information.** Patient self-reports can be useful indicators of treatment progress. In seeking information on treatment progress, it is important for the clinician to avoid conveying a judgmental attitude toward the patient's behavior. Patients should be asked about the quantity and frequency of their drinking, especially during stressful periods (e.g., holidays, celebrations, major life changes). They should be asked about current craving and how they felt over the preceding week (by assigning a rating between 1 and 10, with 1 indicating no craving and 10 the

most intense craving the patient has ever experienced). In addition, patients may be asked whether any episodes have caused particular problems. Identifying patterns of craving over time helps both the patient and the caregiver understand that the pattern of craving fluctuates throughout the day and even over longer periods, indicating the need to continue, adjust, supplement, or discontinue use of a particular medication. Other information that is useful in patient monitoring includes the following:<sup>1,2,13</sup>

- Instruments such as the eight-question *Alcohol Urge Questionnaire* (<https://www.phenxtoolkit.org/index.php?page=Link=browse.protocoldetails&id=520301>)
- Laboratory tests such as the AST, GGT, CDT, EtG, and urine drug screens
- The patient's record of keeping (or not keeping) appointments for medication monitoring
- The frequency of prescription refills, as monitored through the state PDMP<sup>90</sup> or direct contact with the dispensing pharmacy
- Periodic reports from family members (with a signed release of information form)
- Periodic status reports from specialty substance abuse treatment programs, psychiatric referrals, and other psychosocial therapy or support
- Any information about other drugs being used

In addition to securing the patient's PDMP record, obtaining information from family members and significant others can provide useful perspectives on the patient's behavior and level of function, as does contact with or records from clinicians who have treated the patient in the past and information from the prescription benefit provider.<sup>91</sup> Ultimately, the goal of treatment is to improve the patient's quality of life. Specific areas of patient progress for which the patient should be monitored are described in Table 2.

## Adjusting the Treatment Plan

Alcohol use disorder is a chronic illness that, despite treatment, may change in intensity over

time.<sup>2,7,13</sup> If a patient begins to experience problems with adherence, the clinician should assess the patient for underlying medical, psychiatric, or social factors and revisit the treatment plan to determine whether different strategies or treatment modalities (pharmacologic and nonpharmacologic) may be useful. For example, increasing the frequency of monitoring visits or counseling may enhance the patient's ability to manage relapse risks or stressors that are contributing to nonadherence, and switching the patient from oral naltrexone to extended-release injectable naltrexone may enhance adherence to the treatment regimen.

A patient's goals may change over time, and the clinician must adapt to new objectives. Also, as with patients who receive treatment for other chronic diseases, patients receiving treatment for alcohol use disorder may relapse. If this occurs, the provider should consider several options:<sup>2,24</sup>

- Examine social, medical, or behavioral factors that contribute to the patient's alcohol consumption
- Increase monitoring
- Adjust the dose of medication
- Increase or change the intensity of psychosocial services
- Refer the patient for specialty care

## Determining the Duration of Treatment.

Although the optimal duration of treatment is not known, some evidence suggests that treatment should continue for at least 6 months to 1 year.<sup>2,24</sup>

Because alcohol use disorder is a chronic medical problem, patients may need to use medications for long periods of time or may require multiple episodes of pharmacotherapy. In addition, some patients may benefit from treatment with medication over short periods to help them through particularly stressful situations that may elicit cravings for alcohol (e.g., a patient may ask for disulfiram or naltrexone to use when visiting family members who drink excessively).<sup>2,7</sup>

**TABLE 2: Monitoring Health Status and Social Functioning**

Areas for Monitoring	Indicators of Progress
<b>Health</b>	<ul style="list-style-type: none"> <li>Stabilization of medical problems the patient was experiencing before beginning treatment (e.g., lowered blood pressure; improved liver function; control of blood glucose; and stabilization of asthma, cardiomyopathy, encephalopathy, gastritis, ascites, edema)</li> <li>Signs of increased attention to personal health, such as seeing physicians or other health care professionals regularly, increased adherence with prescribed medication regimens not related to alcohol treatment (e.g., asthma or blood pressure medications), and healthful lifestyle changes</li> </ul>
<b>Mental Status<sup>§</sup></b>	<ul style="list-style-type: none"> <li>Reduced irritability and anxiety</li> <li>Improved mood</li> <li>Improved sleep</li> <li>Obtaining appropriate treatment for anxiety disorders, suicidal ideation, depression, or schizophrenia rather than self-medicating with alcohol</li> </ul>
<b>Family/Social Activities</b>	<ul style="list-style-type: none"> <li>Increases in positive time spent with loved ones</li> <li>Reduced interpersonal conflict</li> <li>Engagement in leisure and recreational activities that do not involve alcohol</li> </ul>
<b>Work/School/Vocational Status</b>	<ul style="list-style-type: none"> <li>Resumption of meaningful activities</li> <li>Gaining employment if previously unemployed</li> <li>Engagement in school or other employment preparation</li> <li>Stabilized housing</li> <li>Improved work or school performance</li> </ul>
<b>Legal Status</b>	<ul style="list-style-type: none"> <li>Absence of parole or probation violations (in a patient with legal problems)</li> <li>Absence of new or other legal problems (e.g., driving under the influence charges)</li> </ul>

SOURCE: SAMHSA and NIAAA. (2012, September). *Report of the SAMHSA-NIAAA Consensus Panel on New and Emerging Pharmacotherapies for Alcohol Use Disorders and Related Comorbidities*. Rockville, MD: SAMHSA.

Ideally, a decision to discontinue pharmacotherapy will be based on one of the following reasons:<sup>2,13</sup>

- The patient has maintained stable abstinence over a sustained period and reports substantially diminished craving for alcohol.
- The patient feels ready to discontinue the medication.
- The patient is engaged in ongoing recovery activities involving community supports (e.g., attendance at mutual-help group meetings).

Some patients simply stop taking their medication without consulting the prescriber. Or a patient may ask to discontinue medication use because of side effects or other reasons. Still

other patients must discontinue medication use because of a significant negative laboratory finding or a problem with their physical health status.<sup>2,13</sup> In each situation, the provider should help the patient withdraw from the medication at an appropriate pace and, as indicated, encourage the patient to continue with psychosocial therapies and participation in mutual-help groups.

**Referring a Patient for Higher Levels of Care.** If office-based treatment is not effective or the clinician does not have the resources to meet a particular patient's needs, the patient should be referred for more intensive or specialized services.<sup>2,7</sup> Many specialty treatment programs provide services that address not only immediate withdrawal and craving, but also management of long-term abstinence through pharmacotherapy; case monitoring; individual, group, and

<sup>§</sup> It is recommended that the health care professional administer the PHQ-9 screening tool to objectively assess and monitor the patient's mental status over time. <http://www.drugabuse.gov/sites/default/files/PatientHealthQuestionnaire9.pdf>



family/couples counseling and therapy; other psychosocial services including vocational counseling; and referral to mutual-help groups.<sup>2,24</sup>

A provider who is planning to treat a patient with an alcohol use disorder should become familiar with local treatment resources. Developing relationships with treatment staff members facilitates consultation and referral. In addition, understanding something about a program's treatment duration, modality, philosophy, and

continuing-care options helps the provider match a particular patient to an appropriate treatment program.<sup>13</sup> It also helps the provider prepare the patient for what to expect, thus enhancing adherence with a referral.<sup>2</sup>

Providers can find programs in their areas or throughout the United States by using the Behavioral Health Treatment Services Locator on the SAMHSA Web site at <http://www.findtreatment.samhsa.gov>.

## SUMMARY

Medication-assisted treatment has shown much promise in reducing alcohol use and promoting abstinence in patients diagnosed with alcohol use disorder. Considerable research evidence and consensus among experts support the use of pharmacologic treatments in primary care settings.

A number of FDA-approved medications have been shown to be important elements of such treatment. Although some patients do not benefit from medication-assisted treatment, most do. For each patient deemed an appropriate candidate for medication-assisted treatment, multiple

pharmacologic agents offer a variety of options so that treatment can be tailored to each patient's needs and circumstances.

As new patient care models are encouraged by the Patient Protection and Affordable Care Act (ACA) and the accompanying improvements in the quality and quantity of treatment options that are anticipated as the ACA is implemented, there is considerable potential for expanding the use of medication-assisted treatment as clinicians recognize their safety, efficacy, and cost-effectiveness.

## APPENDIX A: MEMBERS OF THE CONSENSUS PANEL, STAFF, AND CONSULTANTS\*\*

### Members of the Consensus Panel

#### PANEL CHAIR

**Bankole A. Johnson, D.Sc., M.D., M.Phil.**

Professor and Chair  
Department of Psychiatry and Brain  
Science Research Consortium  
Unit  
University of Maryland School of  
Medicine  
Baltimore, Maryland

#### PANEL MEMBERS

**Amanda Abraham, Ph.D.**

Assistant Professor  
Department of Health Policy and  
Management  
University of Georgia  
Athens, Georgia

**Peter R. Cohen, M.D.**

Medical Director  
Maryland Alcohol and Drug Abuse  
Administration  
Catonsville, Maryland

**Marc J. Fishman, M.D.**

Assistant Professor  
Department of Psychiatry  
Johns Hopkins University School of  
Medicine and  
Medical Director  
Maryland Treatment Centers  
Baltimore, Maryland

**J. C. Garbutt, M.D.**

Professor of Psychiatry  
Bowles Center for Alcohol Studies  
University of North Carolina at  
Chapel Hill  
Chapel Hill, North Carolina

**Constance Horgan, Sc.D.**

Professor and Associate Dean for  
Research  
Director  
Institute for Behavioral Health  
Heller School for Social Policy and  
Management  
Brandeis University  
Waltham, Massachusetts

**Andrea King, Ph.D.**

Professor  
Department of Psychiatry and  
Behavioral Neuroscience  
University of Chicago  
Chicago, Illinois

**Henry R. Kranzler, M.D.**

Professor of Psychiatry  
Director, Center for Studies of  
Addiction  
Perelman School of Medicine  
University of Pennsylvania  
Philadelphia, Pennsylvania

**Joseph Liberto, M.D.**

Associate Professor of Psychiatry  
University of Maryland School of  
Medicine and  
Baltimore VA Medical Center  
Baltimore, Maryland

**Paolo Mannelli, M.D.**

Associate Professor of Psychiatry  
Duke University Medical Center  
Chapel Hill, North Carolina

**Tami L. Mark, Ph.D., M.B.A.**

Senior Director  
Analytic Consulting and Research  
Services  
Truven Health Analytics  
Washington, D.C.

**Percy Menzies, M.Pharm.**

President  
Assisted Recovery Centers of  
America  
St. Louis, Missouri

**Charles P. O'Brien, M.D., Ph.D.**

Kenneth Appel Professor of  
Psychiatry  
Treatment Research Center  
University of Pennsylvania  
Philadelphia, Pennsylvania

**Stephanie S. O'Malley, Ph.D.**

Professor of Psychiatry  
Director, Division of Substance  
Abuse Research in Psychiatry  
Yale School of Medicine  
New Haven, Connecticut

**Ismene Petrakis, M.D.**

Professor  
Department of Psychiatry  
Yale School of Medicine  
New Haven, Connecticut

**Helen M. Pettinati, Ph.D.**

Professor  
Department of Psychiatry  
Perelman School of Medicine  
Treatment Research Center  
University of Pennsylvania  
Philadelphia, Pennsylvania

**Lara Ray, Ph.D.**

Assistant Professor  
Department of Psychology and  
Brain Research Institute  
University of California, Los  
Angeles  
Los Angeles, California

**Robert Swift, M.D., Ph.D.**

Professor of Psychiatry and Human  
Behavior  
Brown University  
Providence, Rhode Island

**George Woody, M.D.**

Professor of Psychiatry  
Treatment Research Institute  
University of Pennsylvania  
Philadelphia, Pennsylvania

\*\* Affiliations listed are positions held at the time of the consensus panel in July 2012.

## Staff and Consultants<sup>††</sup>

### CMS STAFF

**Stephen Cha, M.D.**

Chief Medical Officer  
Center on Medicaid and CHIP  
Services  
Centers for Medicare and Medicaid  
Services  
Baltimore, Maryland

**John P. O'Brien**

Senior Policy Advisor  
Centers for Medicare and Medicaid  
Services  
Baltimore, Maryland

### HRSA STAFF

**Seiji Hayashi, M.D., M.P.H.**

Chief Medical Officer  
Bureau of Primary Health Care  
Health Resources and Services  
Administration  
Rockville, Maryland

**Rita Vandivort-Warren, M.S.W.**

Office of Special Health Affairs  
Health Resources and Services  
Administration  
Rockville, Maryland

### NIAAA STAFF

**Joanne Fertig, Ph.D.**

Division of Treatment and Recovery  
Research  
National Institute on Alcohol Abuse  
and Alcoholism/NIH  
Rockville, Maryland

**Bob Huebner, Ph.D.**

Deputy Director  
Division of Treatment and Recovery  
Research  
National Institute on Alcohol Abuse  
and Alcoholism/NIH  
Rockville, Maryland

**Raye Z. Litten, Ph.D.**

Associate Director  
Division of Treatment and Recovery  
Research  
National Institute on Alcohol Abuse  
and Alcoholism/NIH  
Rockville, Maryland

**Kenneth R. Warren, Ph.D.**

Acting Director  
National Institute on Alcohol Abuse  
and Alcoholism/NIH  
Rockville, Maryland

### NIDA STAFF

**Ivan Montoya, M.D., M.P.H.**

Deputy Director  
Division of Pharmacotherapies and  
Medical Consequences of Drug  
Abuse  
National Institute on Drug  
Abuse/NIH  
Bethesda, Maryland

### SAMHSA STAFF

**Melinda Campopiano von Klimo, M.D.**

Medical Advisor  
Division of Pharmacologic Therapies  
Center for Substance Abuse  
Treatment/SAMHSA  
Rockville, Maryland

**H. Westley Clark, M.D., J.D., M.P.H., CAS**

Director  
Center for Substance Abuse  
Treatment/SAMHSA  
Rockville, Maryland

**Peter Delany, Ph.D., LCSW-C**

Director  
Center for Behavioral Health  
Statistics and Quality/SAMHSA  
Rockville, Maryland

**LCDR Brandon T. Johnson, M.B.A.**

Public Health Advisor  
Division of Pharmacologic Therapies  
Center for Substance Abuse  
Treatment/SAMHSA  
Rockville, Maryland

**CDR Erich Kleinschmidt, M.S.W.**

Public Health Advisor  
Division of Pharmacologic Therapies  
Center for Substance Abuse  
Treatment/SAMHSA  
Rockville, Maryland

**Elinore McCance-Katz, M.D., Ph.D.**

Chief Medical Officer  
SAMHSA  
Rockville, Maryland

**Sandrine Pirard, M.D., Ph.D., M.P.H.**

Medical Advisor  
Division of Pharmacologic Therapies  
Center for Substance Abuse  
Treatment/SAMHSA  
Rockville, Maryland

**CDR Alina Salvatore, R.Ph., M.S.**

Public Health Advisor  
Division of Pharmacologic Therapies  
Center for Substance Abuse  
Treatment/SAMHSA  
Rockville, Maryland

### PROJECT CONSULTANTS

**Anton C. Bizzell, M.D.**

President  
The Bizzell Group, LLC  
Silver Spring, Maryland

**Krystyna Isaacs, Ph.D.**

Project Director  
JBS International, Inc.  
North Bethesda, Maryland

**Jane Carlisle Maxwell, Ph.D.**

Senior Research Scientist  
School of Social Work  
University of Texas at Austin  
Austin, Texas

**Joseph Perpich, M.D., J.D.**

Principal & Senior Medical Advisor  
JBS International, Inc.  
North Bethesda, Maryland

### PROJECT DIRECTORS

**Susan Hayashi, Ph.D.**

Vice-President  
JBS International, Inc.  
North Bethesda, Maryland

**Bonnie B. Wilford, M.S.**

Director  
Center for Health Services &  
Outcomes Research  
Senior Principal  
JBS International, Inc.  
North Bethesda, Maryland

---

<sup>††</sup> Affiliations listed are positions held at the time of the project work.

## APPENDIX B: SOURCES OF HELPFUL INFORMATION

### SAMHSA PUBLICATIONS AND WEB SITES

*Detoxification and Substance Abuse Treatment, Treatment Improvement Protocol 45*  
<http://www.store.samhsa.gov/product/TIP-45-Detoxification-and-Substance-Abuse-Treatment/SMA13-4131>

*General Principles for the Use of Pharmacological Agents to Treat Individuals with Co-Occurring Mental and Substance Use Disorders*  
[http://www.ncdsv.org/images/SAMHSA\\_GeneralPrinciplesUsePharmacologicalAgentsTreatIndividualsCo-OccurringMentalSubstanceUseDisorders2012.pdf](http://www.ncdsv.org/images/SAMHSA_GeneralPrinciplesUsePharmacologicalAgentsTreatIndividualsCo-OccurringMentalSubstanceUseDisorders2012.pdf)

*Incorporating Alcohol Pharmacotherapies Into Medical Practice, Treatment Improvement Protocol 49*  
<http://www.store.samhsa.gov/product/TIP-49-Incorporating-Alcohol-Pharmacotherapies-Into-Medical-Practice/SMA13-4380>

*Naltrexone for Extended-Release Injectable Suspension for Treatment of Alcohol Dependence, Substance Abuse Treatment Advisory*  
<http://www.store.samhsa.gov/product/Naltrexone-for-Extended-Release-Injectable-Suspension-for-Treatment-of-Alcohol-Dependence/SMA07-4267>

*Opioid Overdose Toolkit*  
[http://www.store.samhsa.gov/shin/content/SMA13-4742/Overdose Toolkit 2014 Jan.pdf](http://www.store.samhsa.gov/shin/content/SMA13-4742/Overdose_Toolkit_2014_Jan.pdf)

*The Role of Biomarkers in the Treatment of Alcohol Use Disorders, SAMHSA Advisory*  
<http://www.store.samhsa.gov/product/The-Role-of-Biomarkers-in-the-Treatment-of-Alcohol-Use-Disorders-2012-Revision/SMA12-4686>

*SAMHSA's National Registry of Evidence-based Programs and Practices*  
<http://nrepp.samhsa.gov>

*SAMHSA's Screening, Brief Intervention, and Referral to Treatment (SBIRT)*  
<http://www.samhsa.gov/sbirt>

*SAMHSA's Treatment Locator*  
<http://www.samhsa.gov/treatment>

### NIAAA PUBLICATIONS AND WEB SITES

*Alcohol Screening and Brief Intervention for Youth: A Practitioner's Guide*  
<http://www.niaaa.nih.gov/publications/clinical-guides-and-manuals/alcohol-screening-and-brief-intervention-youth/resources>

*Assessing Alcohol Problems: A Guide for Clinicians and Researchers, Second Edition*  
<http://www.pubs.niaaa.nih.gov/publications/AssessingAlcohol>

*Clinical Protocols to Reduce High Risk Drinking in College Students: The College Drinking Prevention Curriculum for Health Care Providers*  
<http://www.collegedrinkingprevention.gov/media/FlemingManual.pdf>

*Exploring Treatment Options for Alcohol Use Disorders, Alcohol Alert, No. 81*  
<http://www.pubs.niaaa.nih.gov/publications/AA81/AA81.htm>

*Helping Patients Who Drink Too Much: A Clinician's Guide, Updated 2005 Edition*  
[http://www.pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians\\_guide.htm](http://www.pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_guide.htm)

*Prescribing Medications for Alcohol Dependence*  
<http://www.pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/PrescribingMeds.pdf>

*Rethinking Drinking: Alcohol and Your Health (available in English and Spanish)*  
<http://www.pubs.niaaa.nih.gov/publications/RethinkingDrinking/OrderPage.htm>

## **MENTORING NETWORK**

Providers' Clinical Support System for Medication Assisted Treatment

<http://www.pcssmat.org>

## **MUTUAL-HELP GROUPS**

Al-Anon Family Groups

<http://www.al-anon.alateen.org>

Alcoholics Anonymous

<http://www.aa.org>

Self-Management and Recovery Training

<http://www.smartrecovery.org>

Women for Sobriety, Inc.

<http://www.womenforsobriety.org>

## **WEB-BASED COURSES**

ASAM e-Live Learning Center

<http://www.softconference.com/asam/default.asp>

ASAM From Assessment to Service Planning and Level of Care Course

<https://www.changecompanies.net/products/product.php?id=ASE2>

ASAM Multidimensional Assessment eLearning

<http://www.changecompanies.net/asamcriteria/elearning.php>

ASAM SBIRT Core Training Program

<http://www.sbirtraining.com>

NIAAA Clinician's Guide Online Training

<http://www.niaaa.nih.gov/publications/clinical-guides-and-manuals/niaaa-clinicians-guide-online-training>

NIAAA Presentations and Videocasts

<http://www.niaaa.nih.gov/publications/presentations-and-videocasts>

## **OTHER WEB SITES**

American Society of Addiction Medicine

<http://www.asam.org>

Georgetown University Medical Center's Ensuring Solutions to Alcohol Problems

<http://www.ensuringsolutions.org>

Gold MS, Aronson, MD. Psychosocial treatment of alcohol use disorder. *Up-to-date* online medical education service, 2013.

<http://www.uptodate.com/contents/psychosocial-treatment-of-alcohol-use-disorder>

National Association of State Controlled Substances Authorities

<http://www.nascsa.org>

U.S. Department of Justice, Drug Enforcement Administration, Office of Diversion Control, State Prescription Drug Monitoring Programs

[http://www.deadiversion.usdoj.gov/faq/rx\\_monitor.htm](http://www.deadiversion.usdoj.gov/faq/rx_monitor.htm)

## **SUGGESTED INSTRUMENTS FOR SCREENING AND MONITORING**

Alcohol Misuse: Screening and Behavioral Counseling Interventions in Primary Care

<http://www.uspreventiveservicestaskforce.org/uspstf/uspdrin.htm>

Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)

[http://www.who.int/substance\\_abuse/activities/assist/en/index.html](http://www.who.int/substance_abuse/activities/assist/en/index.html)

Alcohol Urge Questionnaire (AUQ)

<https://www.phenxtoolkit.org/index.php?pageLink=browse.protocoldetails&id=520301>

Alcohol Use Disorders Identification Test (AUDIT)

[http://www.whqlibdoc.who.int/hq/2001/WHO\\_MS\\_D\\_MSB\\_01.6a.pdf](http://www.whqlibdoc.who.int/hq/2001/WHO_MS_D_MSB_01.6a.pdf)

Clinical Institute Withdrawal Assessment for Alcohol Scale, Revised (CIWA-Ar)

[https://umem.org/files/uploads/1104212257\\_CIWA-Ar.pdf](https://umem.org/files/uploads/1104212257_CIWA-Ar.pdf)

Oregon SBIRT Comprehensive Screening and Brief Intervention Resources

<http://www.sbirtoregon.org>

Problem Oriented Screening Instrument for Teenagers (POSIT)

<http://www.emcdda.europa.eu/html.cfm/index4439EN.html>

## **PUBLISHED GUIDELINES AND REFERENCE TEXTS**

American Psychiatric Association (APA). *Diagnostic and Statistical Manual of Mental Disorders*, Fifth Edition (DSM-5). Washington, DC: American Psychiatric Publishing, 2013.

American Psychological Association (APA). *Understanding Alcohol Use Disorders and Their Treatment*. APA Help Center, 2012.  
<http://www.apa.org/helpcenter/alcohol-disorders.aspx>

American Society of Addiction Medicine (ASAM). *ASAM Patient Placement Criteria*, Third Edition (PPC-3). Philadelphia, PA: Lippincott, Williams & Wilkins, 2013.

American Society of Addiction Medicine (ASAM). *ASAM Patient Placement Criteria: Supplement on Pharmacotherapies for Alcohol Use Disorders*. Philadelphia, PA: Lippincott, Williams & Wilkins, 2010.

American Society of Addiction Medicine (ASAM). *ASAM Principles of Addiction Medicine*, Fifth Edition. Philadelphia, PA: Lippincott, Williams & Wilkins, 2014.

Lingford-Hughes AR, Welch S, Peters L, et al., for the British Association of Psychiatry (BAP). BAP updated guidelines: Evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity. *J Psychopharm*. 2012; 26(7):899-952.

National Clinical Guideline Centre for Acute and Chronic Conditions. *Alcohol-Use Disorders. Diagnosis and Clinical Management of Alcohol-Related Physical Complications*. London, UK: National Institute for Health and Clinical Excellence, 2010.

National Clinical Guideline Centre for Acute and Chronic Conditions. *Alcohol-Use Disorders. Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence*. London, UK: National Institute for Health and Clinical Excellence, 2011.

Veterans Health Administration and Department of Defense (DoD). *VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders in the Primary Care Setting*.  
[http://www.healthquality.va.gov/sud/sud\\_fulltext.pdf](http://www.healthquality.va.gov/sud/sud_fulltext.pdf)



## APPENDIX C: ACKNOWLEDGMENTS

CDR Alina Salvatore, R.Ph., M.S., and LCDR Brandon T. Johnson, M.B.A., of the Division of Pharmacologic Therapies, Center for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Services Administration (SAMHSA), served as the Contracting Officer Representatives for this activity. Robert A. Lubran, M.S., M.P.A., Director of SAMHSA's Division of Pharmacologic Therapies, provided valuable guidance, as did Sandrine Pirard, M.D., Ph.D., M.P.H.; Melinda Campopiano von Klimo, M.D.; CDR Erich Kleinschmidt, M.S.W.; and other experts within SAMHSA, the National Institute on Alcohol Abuse and Alcoholism (NIAAA), other federal agencies, and private-sector organizations.

Members of the SAMHSA-NIAAA Consensus Panel on New and Emerging Pharmacotherapies for Alcohol Use Disorders and Related Comorbidities graciously agreed to serve as peer reviewers of the document. Their many contributions are acknowledged with gratitude.

Special appreciation is extended to Panel Chair Bankole A. Johnson, D.Sc., M.D., M.Phil., and to Kenneth R. Warren, Ph.D., Raye Z. Litten, Ph.D., Joanne Fertig, Ph.D., Bob Huebner, Ph.D., Daniel Falk, Ph.D., and Megan Ryan, M.B.A., of NIAAA.

Susan W. Hayashi, Ph.D., and Bonnie B. Wilford, M.S., served as Project Directors, with valuable assistance from Joseph Perpich, M.D., J.D.; Krystyna Isaacs, Ph.D.; Gwen Solan Littman, M.D.; Candace A. Baker, M.S.W.; Jeffrey Vender, M.L.I.S.; Leotta Britton; and Valerie L. Vivian, M.B.A., of JBS International, Inc.

## REFERENCES

- <sup>1</sup> Substance Abuse and Mental Health Services Administration (SAMHSA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA). *Report of the SAMHSA–NIAAA Consensus Panel on New and Emerging Pharmacotherapies for Alcohol Use Disorders and Related Comorbidities*. Rockville, MD: Substance Abuse and Mental Health Services Administration; July 2012.
- <sup>2</sup> Center for Substance Abuse Treatment. *Incorporating Alcohol Pharmacotherapies Into Medical Practice*. Treatment Improvement Protocol 49. (HHS Publication No. [SMA] 12-4389.) Rockville, MD: Substance Abuse and Mental Health Services Administration; 2009.
- <sup>3</sup> Office of Applied Studies. *Results From the 2013 National Survey on Drug Use and Health: Summary of National Findings*. Section 7.3, Alcohol Use Treatment and Treatment Need. NSDUH Series H-48. (HHS Publication No. [SMA] 14-4863.) Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014.
- <sup>4</sup> D’Amico EJ, Paddock SM, Burnam A, et al. Identification of and guidance for problem drinking by general medical providers: results from a national survey. *Medical Care*. 2005; 43:229-236.
- <sup>5</sup> American Medical Association (AMA). Drug Dependencies as Diseases: Policy H-95.983 of the AMA House of Delegates. Chicago, IL: American Medical Association; 2012. <https://ssl3.ama-assn.org/apps/ecommerce/PolicyFinderForm.pl?site=www.ama-assn.org&uri=%2fresources%2fhtml%2fPolicyFinder%2fpolicyfiles%2fHnE%2fH-95.983.HTM>. Accessed September 4, 2014.
- <sup>6</sup> National Institute on Alcohol Abuse and Alcoholism. Alcohol Use Disorder: A Comparison Between DSM–IV and DSM–5; November 2013. <http://www.pubs.niaaa.nih.gov/publications/dsmfactsheet/dsmfact.pdf>. Accessed September 9, 2014.
- <sup>7</sup> National Institute on Alcohol Abuse and Alcoholism. *Helping Patients Who Drink Too Much: A Clinician’s Guide, Updated 2005 Edition*. (NIH Publication No. 07-3769.) Bethesda, MD: National Institutes of Health; 2007.
- <sup>8</sup> Krishnan-Sarin S, O’Malley S, Krystal JH. Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism. *Alcohol Res Health*. 2008; 31(4):400-407.
- <sup>9</sup> Solberg LI, Maciosek MV, Edwards NM. Primary care intervention to reduce alcohol misuse: ranking its health impact and cost effectiveness. *Am J Prev Med*. 2009; 34(2):143-152.
- <sup>10</sup> Garbutt J. The state of pharmacotherapy for the treatment of alcohol dependence. *Journal of Substance Abuse Treatment*. 2009;36(1):S15-S23.
- <sup>11</sup> Kahan M, Wilson L, Becker L. Effectiveness of physician-based interventions with problem drinkers: a review. *Canadian Med Assoc J*. 1995; 152(6):851-859.
- <sup>12</sup> Smith PC, Schmidt SM, Allenworth-Davies D, Saitz R. Primary care validation of a single-question alcohol screening test. *J General Int Med*. 2009; 24:783-788.
- <sup>13</sup> Federation of State Medical Boards. *Model Policy on the Treatment of Opioid Addiction in the Medical Office*. Dallas, TX: The Federation; 2013.
- <sup>14</sup> Conigliaro J, Delos Reyes C, Parran TV, et al. Principles of screening and early intervention. In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, eds. *Principles of Addiction Medicine*. 3rd ed. Chevy Chase, MD: American Society of Addiction Medicine; 2003:119-139.
- <sup>15</sup> Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. *Am J Drug Alcohol Abuse*. 2011; 37:1-11.



- <sup>16</sup> Litten RZ, Bradley AM, Moss HB. Alcohol biomarkers in applied settings: recent advances and future research opportunities. *Alcohol Clin Exp Res*. 2010; 34:955-967.
- <sup>17</sup> Yersin B, Nicolet JF, Dercrey H, et al. Screening for excessive alcohol drinking: comparative value of carbohydrate-deficient transferrin, gamma-glutamyltranserase, and mean corpuscular volume. *Arch Internal Med*. 1995; 155(17):1907-1911.
- <sup>18</sup> Sillanaukee P, Aalto M, Seppa K. Carbohydrate-deficient transferrin and conventional alcohol markers as indicators for brief intervention among heavy drinkers in primary health care. *Alcohol Clin Exp Res*. 1998; 22(4):892-896.
- <sup>19</sup> Topic A, Djukic M. Diagnostic characteristics and application of alcohol biomarkers. *Clin Lab*. 2013; 59(3-4):233-245. Review.
- <sup>20</sup> Kissack JC, Bishop J, Roper AL. Ethylglucuronide as a biomarker for ethanol detection. *Pharmacother*. 2008; 28:769-781.
- <sup>21</sup> Allen JP, Wurst FM, Thon N, Litten RZ. Assessing the drinking status of liver transplant patients with alcoholic liver disease. *Liver Transp*. 2013; 19:369-376.
- <sup>22</sup> Skipper GE, Thon N, DuPont RL, Baxter L, Wurst FM. Phosphatidylethanol: the potential role in further evaluating low positive urinary ethyl glucuronide and ethyl sulfate results [published online ahead of print]. *Alcohol Clin Exp Res*.
- <sup>23</sup> Center for Substance Abuse Treatment. The role of biomarkers in the treatment of alcohol use disorders. *Substance Abuse Treatment Advisory*. 2006; 5(4).  
[http://www.kap.samhsa.gov/products/manuals/advisory/pdfs/0609\\_biomarkers.pdf](http://www.kap.samhsa.gov/products/manuals/advisory/pdfs/0609_biomarkers.pdf). Accessed September 9, 2014.
- <sup>24</sup> Fishman MJ, Mee-Lee D, Shulman GD, Kolodner G, Wilford BB, eds. *ASAM Patient Placement Criteria: Supplement on Pharmacotherapies for Alcohol Use Disorders*. Philadelphia, PA: Lippincott, Williams & Wilkins; 2010.
- <sup>25</sup> Center for Substance Abuse Treatment. *Detoxification and Substance Abuse Treatment*. Treatment Improvement Protocol 45. (HHS Publication No. [SMA] 08-4131.) Rockville, MD: Substance Abuse and Mental Health Services Administration; 2006.
- <sup>26</sup> Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). *Brit J Addiction*. 1989; 84(11):1353-1357.
- <sup>27</sup> Mayo-Smith MF. Management of alcohol intoxication and withdrawal. In Ries R, Fiellin DA, Miller S, Saitz R, eds. *Principles of Addiction Medicine*, 4th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2009: 559-572.
- <sup>28</sup> McCaul ME, Petry NM. The role of psychosocial treatments in pharmacotherapy for alcoholism. *Am J Addiction*. 2003; 12(suppl 1):S41-S52.
- <sup>29</sup> Alcoholics Anonymous. *The AA Member—Medications and Other Drugs: Report From a Group of Physicians in AA*. New York, NY: Alcoholics Anonymous World Services; 1984.
- <sup>30</sup> Kranzler HR, Rosenthal RN. Dual diagnosis: alcoholism and co-morbid psychiatric disorders. *Am J Addiction*. 2003; 12(suppl 1):S26-S40.
- <sup>31</sup> Center for Substance Abuse Treatment. *Substance Abuse Treatment for Persons With Co-Occurring Disorders*. Treatment Improvement Protocol 42. (HHS Publication No. [SMA] 05-3992.) Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005.
- <sup>32</sup> National Institute on Drug Abuse (NIDA). *NIDA Research Report Series: Comorbidity*. (NIH Publication Number 10-5771.) Bethesda, MD: National Institutes of Health; 2010.
- <sup>33</sup> Brown SA, McGue M, Maggs J, et al. A developmental perspective on alcohol and youths 16 to 20 years of age. *Pediatrics*. 2008; 121(suppl 4):S290-S310.

- <sup>34</sup> Hingson RW, Heeren T, Winter MR. Age at drinking onset and alcohol dependence: age at onset, duration, and severity. *Arch Ped Adolescent Med*. 2006; 160(7):739-746.
- <sup>35</sup> Squeglia LM, Jacobu J, Tapert SF. The influence of substance use on adolescent brain development. *Clinical EG Neuroscience J*. 2009; 40(1):31-38.
- <sup>36</sup> Clark DB. Pharmacotherapy for adolescent alcohol use disorder. *CNS Drugs*. 2012; 26(7):559-569.
- <sup>37</sup> Grant BF, Dawson DA. Age at onset of alcohol use and its association with DSM-IV alcohol abuse and dependence: Results from the National Longitudinal Alcohol Epidemiologic Survey. *J Sub Abuse*. 1997; 9:103-110.
- <sup>38</sup> Pruet D, Waterman EH, Caughey AB. Fetal alcohol exposure: consequences, diagnosis, and treatment. *Obst Gynecol Survey*. 2013; 68(1):62-69.
- <sup>39</sup> FDA Pregnancy Categories. Chemical Management Emergency Medical Management, Department of Health & Human Services Web site. <http://chemm.nlm.nih.gov/pregnancycategories.htm>. Published June 2011. Accessed September 10, 2014.
- <sup>40</sup> Lingford-Hughes AR, Welch S, Peters L, et al., for the British Association of Psychiatry (BAP). BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity. *J Psychopharm*. 2012; 1-54.
- <sup>41</sup> Moore AA, Whiteman EJ, Ward KT. Risks of combined alcohol/medication use in older adults. *Am J Geriatric Pharmacotherapy*. 2007; 5:64-74.
- <sup>42</sup> Reid MC, Boutros NN, O'Connor PG, et al. The health-related effects of alcohol use in older persons: a systematic review. *Substance Abuse*. 2002; 23:146-164.
- <sup>43</sup> Simoni-Wastila L, Yang HK. Psychoactive drug abuse in older adults. *Am J Geriatric Pharmacotherapy*. 2006; 4:380-394.
- <sup>44</sup> Han B, Gfroerer JC, Collive JD, et al. Substance use disorder among older adults in the United States in 2020. *Addiction*. 2009; 104:88-96.
- <sup>45</sup> Center for Substance Abuse Treatment. *Substance Abuse Among Older Adults*. Treatment Improvement Protocol 26. (HHS Publication No. [SMA] 08-3918.) Rockville, MD: Substance Abuse and Mental Health Services Administration; 2001.
- <sup>46</sup> Oslin DW. Evidence-based treatment of geriatric substance abuse. *Psych Clin N America*. 2005; 28:897-911.
- <sup>47</sup> Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. *Biochem Pharmacology*. 2008; 75(1):34-56.
- <sup>48</sup> Swift R. Emerging approaches to managing alcohol dependence. *Am J Health Sys Pharmacy*. 2007; 64(5 suppl 3):S12-S22.
- <sup>49</sup> Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence. *J Am Med Assoc*. 1999; 281(14):1318-1325.
- <sup>50</sup> Antabuse (disulfiram) prescription drug label. U.S. National Library of Medicine Web site. <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0ca0e1f-9641-48d5-9367-e5d1069e8680>. Published August 2014. Accessed September 2, 2014.
- <sup>51</sup> Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. *Drug Safety*. May 1999; 20(5):427-435. Review.
- <sup>52</sup> Youick JJ, Faiman MD. Disulfiram metabolism as a requirement for the inhibition of rat liver mitochondrial low Km aldehyde dehydrogenase. *Biochem Pharmacology*. 1991; 42(7):1361-1366.
- <sup>53</sup> Williams SH. Medications for treating alcohol dependence. *Am Family Phys*. 2005; 72(9):1775-1780.
- <sup>54</sup> Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today? *Addiction*. 2004; 99(1):21-24.

- <sup>55</sup> Laaksonen E, Koski-Jannes A, Salaspuro M, et al. A randomized, multicenter, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. *Alcohol*. 2008; 43(1):53-61.
- <sup>56</sup> Brewer C, Myers RJ, Johnsen J. Does disulfiram help to prevent relapse in alcohol abuse? *CNS Drugs*. 2000; 14:329-341.
- <sup>57</sup> Martin B, Clapp L, Alfors J, et al. Adherence to court-ordered disulfiram at fifteen months: a naturalistic study. *J Sub Abuse Treat*. 2004; 26:233-236.
- <sup>58</sup> Vivitrol (extended release naltrexone) prescription drug label. U.S. National Library of Medicine Web site. <http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74696d65-6973-6275-7461-77696e646f77>. Published July 2013. Accessed October 14, 2014.
- <sup>59</sup> Bouza C, Angeles M, Munoz A, et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. *Addiction*. 2004; 99:811-828.
- <sup>60</sup> Snyder JL, Bowers TG. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials. *Am J Drug Alcohol Abuse*. 2008; 34(4):449-461.
- <sup>61</sup> National Institute for Health and Clinical Excellence (NICE). *Naltrexone for the Management of Opioid Addiction*. Technology Appraisal Guidance No. 115. London, UK: NICE; 2010.
- <sup>62</sup> Gastfriend DR. Intramuscular extended-release naltrexone: Current evidence. *Ann NY Acad Sciences*. 2011; 1216:144-166.
- <sup>63</sup> Food and Drug Administration (FDA). Vivitrol (naltrexone for extended-release injectable suspension: NDA 21-897C)—briefing document/background package. Rockville, MD: FDA Pharmacologic Drugs Advisory Committee Meeting; 2010.
- <sup>64</sup> Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. *Intl J Neuropsychopharmacology*. 2005; 8(2):267-280.
- <sup>65</sup> O'Malley SS. Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse. *Alcohol*. 1996; 31(1):77-81.
- <sup>66</sup> Garbutt JC, Kranzler HR, O'Malley SS, et al. for the Vivitrol Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. *J Amer Med Assoc*. 2005; 293:1617-1625.
- <sup>67</sup> O'Malley SS, Garbutt JC, Dong Q, et al. Efficacy of extended-release naltrexone in alcohol dependent patients who are abstinent before treatment. *J Clin Psychopharm*. 2007; 27(5):507-512.
- <sup>68</sup> Alkermes. Vivitrol prescribing information. Waltham, MA: Author, July 2013. [http://www.Vivitrol.com/Content/pdf/prescribing\\_info.pdf](http://www.Vivitrol.com/Content/pdf/prescribing_info.pdf) Accessed March 12, 2015.
- <sup>69</sup> Johnson BA. Naltrexone long-acting formulation in the treatment of alcohol dependence. *J Therapeutics Clin Risk Management*. 2007; 3(5):741-749.
- <sup>70</sup> Anton RF, Oroszi G, O'Malley SS, et al. An evaluation of  $\mu$ -opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. *Arch General Psych*. 2008; 65(2):135-144.
- <sup>71</sup> Volpicelli JR, Watson NT, King AC, et al. Effect of naltrexone on alcohol "high" in alcoholics. *Am J Psychiatry*. 1995; 152:613-615.
- <sup>72</sup> Monterosso JR, Flannery BA, Pettinati HM, et al. Predicting treatment response to naltrexone: the influence of craving and family history. *Am J Addictions*. 2001; 10(3):258-268.
- <sup>73</sup> Rubio G, Ponce G, Rodriguez-Jimenez R, et al. Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone? *Alcohol*. 2005; 40(3):227-233.

- <sup>74</sup> Manelli P, Peindl KS, Wu L. Pharmacological enhancement of naltrexone treatment for opioid dependence: a review. *Sub Abuse Rehab*. 2011; (2):113-123.
- <sup>75</sup> Scott LJ, Figget DP, Keam SJ, et al. Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence. *CNS Drugs*. 2005; 19(5):445-464.
- <sup>76</sup> Witkiewitz K, Saville K, Hamreus K. Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. *Therapeutics Clin Risk Management*. 2012; 8:45-53.
- <sup>77</sup> Verheul R, Leher P, Geerlings PJ, et al. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1,485 alcohol-dependent patients. *Psychopharm (Berl)*. 2005; 178(2-3):167-173.
- <sup>78</sup> Mason BJ, Goodman AM, Chabac S, et al. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. *J Psych Research*. 2006; 40:383-393.
- <sup>79</sup> Mann K, Leher P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. *Alcohol Clin Exp Res*. 2004; 28(1):51-63.
- <sup>80</sup> Sigmon SC, Bisaga A, Nunes EV et al. Opioid detoxification and naltrexone induction strategies: Recommendations for clinical practice. *Am J Drug Alcohol Abuse* 2012; 38(3):187–199.
- <sup>81</sup> Center for Substance Abuse Treatment. Naltrexone: Extended-release injectable suspension for treatment of alcoholism dependence. *Substance Abuse Treatment Advisory* 2007 Spring;6(1):1–6.
- <sup>82</sup> Substance Abuse and Mental Health Services Administration. *Opioid Overdose Toolkit*. Rockville, MD: SAMHSA; 2014.
- <sup>83</sup> Kranzler HR, Rosenthal RN. Dual diagnosis: alcoholism and co-morbid psychiatric disorders. *Am J Addiction*. 2003; 12(suppl 1):S26-S40.
- <sup>84</sup> Center for Substance Abuse Treatment. *Substance Abuse Treatment for Persons With Co-Occurring Disorders*. Treatment Improvement Protocol 42. (HHS Publication No. [SMA] 05-3992.) Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005.
- <sup>85</sup> National Institute on Drug Abuse (NIDA). *NIDA Research Report Series: Comorbidity*. (NIH Publication Number 10-5771.) Bethesda, MD: National Institutes of Health; 2010.
- <sup>86</sup> Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years' observations on male British doctors. *British Medical Journal*. 1994; 309:901.
- <sup>87</sup> Holman CD, English DR, Milne E, et al. Meta-analysis of alcohol and all-cause mortality: A validation of NHMRC recommendations. *Med J Australia*. 1996; 164(3):141-145.
- <sup>88</sup> Cherpitel CJ. Alcohol and casualties: A comparison of emergency room and coroner data. *Alcoholism*. 1994; 29(2):211-218.
- <sup>89</sup> Bradley KA, Badrinath S, Bush K, et al. Medical risks for women who drink alcohol. *J Gen Internal Med*. 1998; 13(9):627-639.
- <sup>90</sup> State Prescription Drug Monitoring Programs. Department of Justice, Drug Enforcement Agency, Office of Diversion Control Web Site. <http://www.deadiversion.usdoj.gov/>. Updated October 2011. Accessed August 15, 2014.
- <sup>91</sup> Finch JW, Kamien JB, Amass L. Two-year experience with buprenorphine/naloxone (Suboxone) for maintenance treatment of opioid dependence within a private practice setting. *J Addict Med*. 2007 Jun;1(2):104–110.